[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 460
1. Zhang JW, Zhao H, Bai XF, Fang Y, Wang CF, Zhao P: [Analysis of risk factors of stress-related ulcer and gastrointestinal hemorrhage after pancreaticoduodenectomy]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 1999 to July 2007, 285 periampullary cancer patients underwent pancreaticoduodenectomy in our hospital.
  • Pathological examination showed pancreatic cancer in 5 cases, duodenal cancer in 8, common bile duct cancer in 10, ampullary carcinoma in 11, and solid-pseudopapillary tumors in 1.
  • [MeSH-major] Common Bile Duct Neoplasms / complications. Gastrointestinal Hemorrhage / etiology. Pancreatic Neoplasms / complications. Pancreaticoduodenectomy / adverse effects. Peptic Ulcer / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Alcoholism / complications. Ampulla of Vater. Bilirubin / blood. Duodenal Neoplasms / complications. Duodenal Neoplasms / pathology. Duodenal Neoplasms / surgery. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prealbumin / metabolism. Retrospective Studies. Risk Factors. Stress, Psychological / complications. Young Adult


2. Eswaran SL, Sanders M, Bernadino KP, Ansari A, Lawrence C, Stefan A, Mattia A, Howell DA: Success and complications of endoscopic removal of giant duodenal and ampullary polyps: a comparative series. Gastrointest Endosc; 2006 Dec;64(6):925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Success and complications of endoscopic removal of giant duodenal and ampullary polyps: a comparative series.
  • BACKGROUND: Increasing reports suggest that endoscopic removal of benign ampullary and duodenal polyps is safe and frequently definitive; however, most reported polyps have been small in size (<3 cm).
  • When the ampulla was involved, biductal sphincterotomy and prophylactic pancreatic duct stent placement was performed first, followed by saline solution-assisted piecemeal polypectomy, argon plasma coagulation, selective endoclip placement, and recovery of all polyp fragments.
  • INTERVENTIONS: Endoscopic removal of duodenal and ampullary adenomas.
  • RESULTS: The outcomes of small and large adenoma removal include mean number of endoscopic retrograde cholangiopancreatographies required for complete removal (2.09 vs 2.56, P = .392), number of complications (4.5% vs 13.9%, P = .375), discovery of unsuspected cancer (0% vs 10.3%, P = .242), and final definitive resolution (100% vs 86.2%, P = .124).
  • CONCLUSIONS: Large (>/=3 cm) ampullary and duodenal polyps comprised 56.9% of our endoscopically treated cases and present special challenges to definitive endoscopic removal.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Duodenal Neoplasms / surgery. Endoscopy, Digestive System / methods. Polyps / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140900.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Khaimook A, Borkird J, Alapach S: The first successful laparoscopic Whipple procedure at Hat Yai Hospital: surgical technique and a case report. J Med Assoc Thai; 2010 Sep;93(9):1098-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whipple procedure is the most complex abdominal surgical procedure to treat periampullary carcinoma.
  • The patient was a 40-year-old, Thai-Muslim female, with the diagnosis of ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Laparoscopy / methods. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20873085.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, Deng J, Shen MC, Wang BS, Han TQ, Zhang BH, Cohen-Webb H, Yeager M, Welch R, Chanock S, Fraumeni JF Jr, Hsing AW: Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis; 2006 Jun;27(6):1251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.
  • There is evidence that chronic inflammation predisposes to biliary tract cancer and that use of non-steroidal anti-inflammatory drugs (NSAIDs) is protective.
  • Although the mechanisms by which NSAIDs lower cancer risk remain unclear, NSAIDs reduce prostaglandin production by blocking prostaglandin-endoperoxide synthase 2 (PTGS2, commonly known as COX-2), an enzyme induced by proinflammatory stimuli that is often overexpressed in malignant tissue.
  • Since variants in the PTGS2 gene may modify the expression or function of its encoded enzyme to modulate the inflammatory response in the biliary tract, we examined the associations of eight PTGS2 polymorphisms (-645C-->T; Ex3 -8G-->C; IVS5 -275T-->G; IVS7 +111T-->C; Ex10 +127T-->C; Ex10 +686 --->ATTAT-->TTATA; Ex10 +837T-->C; Ex10 -90C-->T) with biliary tract cancer and stones in a population-based case-control study conducted in Shanghai, China.
  • Genotyping was performed for 411 patients with biliary tract cancer (237 gallbladder, 127 extrahepatic bile duct and 47 ampulla of Vater), 895 patients with biliary stones (673 gallbladder, 222 bile duct), and 786 healthy individuals randomly selected from the population.
  • Significant associations were seen only between the Ex10 +837T-->C marker and bile duct cancer risk.
  • Relative to individuals with the TT genotype, those carrying the C allele (TC or CC genotype) had a 1.8-fold (95% confidence interval: 1.2-2.7) risk of bile duct cancer.
  • Inferred haplotypes including this risk-conferring allele were also associated with increased bile duct cancer risk of similar magnitude.
  • Our results suggest that a common PTGS2 variant increases bile duct cancer risk.
  • Further investigation is needed to confirm and extend our findings in studies of biliary tract cancer that more comprehensively examine PTGS2 and other inflammation-related genes.
  • [MeSH-major] Biliary Tract Neoplasms / genetics. Cyclooxygenase 2 / genetics. Gallstones / diagnosis. Genetic Predisposition to Disease. Membrane Proteins / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361272.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


5. Liu N, Liang H, Li Q, Wang DC, Zhang RP, Wang JC, Hao XS: [Determinants of long-term survival in 38 patients with carcinoma of ampulla of Vater treated by local resection]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):629-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Determinants of long-term survival in 38 patients with carcinoma of ampulla of Vater treated by local resection].
  • OBJECTIVE: To investigate determinants of long-term survival for carcinoma of ampulla of Vater treated by local resection.
  • On deciding for resection, the common bile duct was probe explored which guided the circumferential ring resection 1 cm, away from the tumor, including all layers of duodenum, ampula and partial bile and terminal pancreatic ducts and the posterial wall of duodenum was completed in steps.
  • Meticulous care was taken not to suture the pancreatic duct and endotheliation was ensured at the mouth of common bile duct and duodenum.
  • Preferably it is indicated only in high risk patients with a pT1 and well differentiated ampullary cancer smaller than 1 cm in diameter.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438877.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Kamisawa T, Tu Y, Egawa N, Tsuruta K, Okamoto A: A new diagnostic endoscopic tool for autoimmune pancreatitis. Gastrointest Endosc; 2008 Aug;68(2):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although it is of utmost importance that AIP be differentiated from pancreatic cancer, AIP is sometimes difficult to differentiate from locally advanced pancreatic cancer.
  • PATIENTS: Ten AIP patients, 10 patients with pancreatic cancer, and 10 patients with papillitis.
  • INTERVENTIONS: Immunoglobulin (Ig)G4-immunostaining of biopsy specimens obtained from the major duodenal papilla.
  • RESULTS: Significant infiltration of IgG4-positive plasma cells (> or = 10/HPF) was observed in the major duodenal papilla of all 8 AIP patients with pancreatic head involvement.
  • Moderate infiltration of IgG4-positive plasma cells (4-9/HPF) was detected in 1 patient with pancreatic head cancer, but there were rare (< or = 3/HPF) IgG4-positive plasma cells infiltrating the major duodenal papilla in 2 AIP patients who only had pancreatic body and/or tail involvement, 9 patients with pancreatic cancer, and 10 patients with papillitis.
  • CONCLUSIONS: IgG4 immunostaining of biopsy specimens obtained from the major duodenal papilla may be useful for supporting a diagnosis of AIP with pancreatic head involvement.
  • [MeSH-major] Ampulla of Vater / pathology. Autoimmune Diseases / diagnosis. Cholangitis / pathology. Pancreatic Neoplasms / pathology. Pancreatitis / immunology. Pancreatitis / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. CD4-Positive T-Lymphocytes / immunology. Cholangiopancreatography, Endoscopic Retrograde / methods. Diagnosis, Differential. Duodenoscopy / methods. Female. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunohistochemistry. Male. Middle Aged. Probability. Prospective Studies. Risk Assessment. Sensitivity and Specificity


7. Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N, Kirimlioğlu V: The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. Turk J Gastroenterol; 2009 Mar;20(1):41-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
  • Biliary neoplasms are classified into intra- and extrahepatic cholangiocarcinoma (Klatskin tumor, middle and distal extrahepatic tumors), gallbladder adenocarcinoma, and ampullary carcinoma.
  • METHODS: Ten gallbladder adenocarcinoma, 8 distal bile duct carcinomas (distal cholangiocarcinoma), 8 Klatskin tumors, 8 intrahepatic cholangiocarcinomas and 10 ampullary carcinomas were included in the study.
  • MMP-2 expression was detected in the distal part of the biliary ducts, in 75% (6/18) of cases and in the nontumoral epithelia of the ampullary region in 50% (5/10) of cases.
  • The metaplastic and dysplastic epithelia were positively stained in all of the gallbladder adenocarcinoma, distal cholangiocarcinoma and ampullary tumors.
  • The gallbladder adenocarcinoma, distal cholangiocarcinoma and ampullary carcinomas expressed MMP-2 in 30%, 37% and 40% of the cases, respectively.
  • MMP-9 and MMP- 14 were present in metaplasia, dysplasia carcinoma sequence in all of the bile tract tumors, suggesting that MMPs play an important role in carcinogenesis.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Ampulla of Vater / enzymology. Ampulla of Vater / pathology. Disease Progression. Gallbladder Neoplasms / metabolism. Gallbladder Neoplasms / pathology. Hepatic Duct, Common / enzymology. Hepatic Duct, Common / pathology. Humans. Immunohistochemistry. Klatskin Tumor / metabolism. Klatskin Tumor / pathology. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330734.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


8. Hsing AW, Zhang M, Rashid A, McGlynn KA, Wang BS, Niwa S, Ortiz-Conde BA, Goedert JJ, Fraumeni JF Jr, O'Brien TR, Gao YT: Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer; 2008 Apr 15;122(8):1849-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China.
  • To test the HBV hypothesis, we examined the relationship of HBV/HCV infection with risks of biliary tract cancer and biliary stones in a population-based case-control study conducted in Shanghai, China.
  • HBsAg seroprevalence was 7.3% among population controls and 14.2% among patients with extrahepatic bile duct cancer, resulting in a 2.4-fold risk of extrahepatic bile duct cancer (95% CI 1.2-4.5).
  • No association was found for cancers of the gallbladder (prevalence 8.2%) or the ampulla of Vater (6.1%), or for stones in the gallbladder (10.1%) or bile duct (9.3%).
  • In Shanghai, an HBV endemic area, chronic HBV infection was associated with a 2.4-fold risk of extrahepatic bile duct cancer.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076042.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


9. Hsu HP, Shan YS, Lai MD, Lin PW: Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther; 2010 Jul 15;10(2):144-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival.
  • PURPOSE: Tumor-associated macrophages (TAMs) promote cancer cell proliferation and distant metastases.
  • Osteopontin (OPN) is overexpressed in several human cancer cells and in TAMs.
  • Therefore, we set out to determine the role of OPN-expressing macrophages in cancer.
  • RESULTS: In 100 ampullary cancers, diffuse cytoplasmic positivity for OPN was found in infiltrating TAMs in 36 patients and marginal TAMs in 32 patients; OPN(+) macrophages were absent in 32 patients.
  • Expression patterns of OPN in TAMs were associated with pancreatic invasion, tumor stage, TNM stage, lymphovascular invasion and recurrence with peritoneal carcinomatosis.
  • Macrophage-associated cytokine expression in ampullary cancer cells was also assessed; levels of macrophage migration inhibitory factor (MIF) in cancer cells were higher than in normal duodenal mucosa.
  • EXPERIMENTAL DESIGN: Specimens from ampullary cancer patients at National Cheng Kung University Hospital were collected for immunohistochemistry.
  • CONCLUSIONS: Expression of OPN and location of TAMs in bulky ampullary cancer predict recurrence.
  • In addition, cytoplasmic staining of MIF is enhanced in ampullary cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Biomarkers, Tumor / metabolism. Common Bile Duct Neoplasms / pathology. Macrophage Migration-Inhibitory Factors / metabolism. Macrophages / metabolism. Osteopontin / metabolism. RNA, Neoplasm / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495367.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Neoplasm; 106441-73-0 / Osteopontin
  •  go-up   go-down


10. Defrain C, Chang CY, Srikureja W, Nguyen PT, Gu M: Cytologic features and diagnostic pitfalls of primary ampullary tumors by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer; 2005 Oct 25;105(5):289-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features and diagnostic pitfalls of primary ampullary tumors by endoscopic ultrasound-guided fine-needle aspiration biopsy.
  • BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-guided FNAB) is highly sensitive and specific in cytologic diagnosis and clinical staging of malignant neoplasms of the gastrointestinal tract, pancreas, liver, and lymph nodes.
  • However, no study has been performed to evaluate its accuracy, sensitivity, specificity, and the cytomorphologic features of suspected primary ampullary tumors.
  • METHODS: All EUS-guided FNABs of suspected primary ampullary lesions at the University of California Irvine Medical Center (Orange, CA) from January 1998 to September 2004 were retrospectively retrieved.
  • The number of passes necessary to arrive at a preliminary diagnosis during adequacy assessment was documented.
  • Thirteen patients had a diagnosis that was negative for malignant cells.
  • CONCLUSIONS: EUS-guided FNAB was accurate, sensitive, and specific in the assessment of suspected primary ampullary masses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986397.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Itoi T, Tsuji S, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T, Ishii K, Ikeuchi N, Igarashi M, Gotoda T, Moriyasu F: A novel approach emphasizing preoperative margin enhancement of tumor of the major duodenal papilla with narrow-band imaging in comparison to indigo carmine chromoendoscopy (with videos). Gastrointest Endosc; 2009 Jan;69(1):136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach emphasizing preoperative margin enhancement of tumor of the major duodenal papilla with narrow-band imaging in comparison to indigo carmine chromoendoscopy (with videos).
  • BACKGROUND: Endoscopic papillectomy (EP) has been recognized as a safe and reliable treatment for tumor of the duodenal papilla.
  • OBJECTIVE: Our purpose was to prospectively assess the enhancement of the lateral margins of tumor of the duodenal papilla for the treatment of EP by comparing narrow-band imaging (NBI) and indigo carmine (IC) chromoendoscopy.
  • PATIENTS: Fourteen consecutive cases of tumors of the major duodenal papilla.
  • MAIN OUTCOME MEASUREMENT: Histologic evaluation of diagnosis of NBI and IC by comparison with en bloc tissue.
  • CONCLUSION: This study demonstrated the feasibility and a certain degree of efficacy of NBI for enhancement of the tumor margin of duodenal papilla.
  • [MeSH-major] Adenoma / pathology. Ampulla of Vater / pathology. Diagnostic Imaging / methods. Duodenal Neoplasms / pathology. Duodenoscopy / methods. Image Enhancement / methods. Indigo Carmine

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026411.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] D3741U8K7L / Indigo Carmine
  •  go-up   go-down


12. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N: Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol; 2006 Sep;36(9):552-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
  • BACKGROUND: Standard chemotherapy for advanced biliary tract cancer has not been established.
  • The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and ampulla of Vater cancer, which was not amenable to surgery, were eligible for the study.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin was well tolerated and showed preliminary moderate activity against advanced biliary tract cancer.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887837.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 1-UFT protocol
  •  go-up   go-down


13. van Oost FJ, Luiten EJ, van de Poll-Franse LV, Coebergh JW, van den Eijnden-van Raaij AJ: Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol; 2006 Jun;32(5):548-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study.
  • AIMS: To gain insight into the quality of pancreatic cancer surgery in 10 low-volume (median sized) hospitals, each serving 150,000-250,000 people, in the Comprehensive Cancer Centre South (CCCS) area and of referred patients to academic centres to determine the need for further regionalization.
  • METHOD: The population-based Eindhoven Cancer Registry was used to select all patients in the CCCS area with pancreatic, peri-ampullary and ampullary cancer diagnosed between January 1, 1995 and April 30, 2000 (N = 1130).
  • RESULTS: For all pancreatic carcinoma resections, the 3-month survival rate was 82%, varying from 95% for referred patients to 76% for patients treated within the region (p = 0.014).
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreatic Neoplasms / surgery. Registries
  • [MeSH-minor] Academic Medical Centers. Adult. Age Factors. Aged. Aged, 80 and over. Catchment Area (Health). Female. Hospitals, General. Hospitals, University. Humans. Male. Middle Aged. Needs Assessment. Neoplasm Staging. Netherlands. Population Surveillance. Referral and Consultation. Sex Factors. Social Class. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569495.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Botsios D, Zacharakis E, Lambrou I, Tsalis K, Christoforidis E, Kalfadis S, Zacharakis E, Betsis D, Dadoukis I: Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol; 2005 Aug 30;2:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Our local experience with the surgical treatment of ampullary cancer.
  • BACKGROUND: The aim of this study is to report the outcome after surgical treatment of 32 patients with ampullary cancers from 1990 to 1999.
  • METHODS: Twenty-one of them underwent pancreaticoduodenectomy and 9 local excision of the ampullary lesion.
  • RESULTS: When the final histological diagnosis was compared with the preoperative histological finding on biopsy, accurate diagnosis was preoperatively established in 24 patients.
  • Following local excision of the ampullary cancer, the survival rate at 3 and 5 years was 77.7% and 33.3% respectively.
  • CONCLUSION: In this series, local resection was a safe option in patients with significant co-morbidity or small ampullary tumors less than 2 cm in size, and was associated with satisfactory long-term survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):593-6; discussion 596-7 [2589595.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):356-68 [7682052.001]
  • [Cites] Arch Surg. 1994 Oct;129(10):1075-80 [7944938.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Chirurg. 1993 Jun;64(6):476-82 [8359060.001]
  • [Cites] Leber Magen Darm. 1993 Jan;23(1):13-8, 21-3 [8445972.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Eur J Surg Oncol. 1996 Aug;22(4):366-71 [8783654.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Surgery. 1986 Oct;100(4):716-23 [3764694.001]
  • [Cites] Acta Chir Scand. 1986 Aug-Sep;152:537-9 [3788399.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Br J Surg. 1987 Feb;74(2):116-8 [3815026.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):72-3 [3947884.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):46-52 [3966641.001]
  • [Cites] J R Coll Surg Edinb. 1982 May;27(3):154-7 [7108832.001]
  • [Cites] Endoscopy. 1981 Jul;13(4):154-6 [7250083.001]
  • (PMID = 16131399.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215507
  •  go-up   go-down


15. Aimoto T, Uchida E, Nakamura Y, Katsuno A, Chou K, Tajiri T, Naito Z: Malignant afferent loop obstruction following pancreaticoduodenectomy: report of two cases. J Nippon Med Sch; 2006 Aug;73(4):226-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant afferent loop obstruction following pancreaticoduodenectomy: report of two cases.
  • We report two cases of malignant afferent loop obstruction following pancreaticoduodenectomy (PD). Case 1.
  • A 70-year-old woman, who had undergone PD for pancreatic cancer, was referred to our hospital because of fever, jaundice, and abdominal pain.
  • Laparotomy confirmed the diagnosis of local recurrent tumor causing occlusion of the afferent limb, and Roux-en-Y bypass was performed. Case 2.
  • A 72-year-old man, who had undergone PD for cancer of the major papilla, was hospitalized with a high-grade fever and epigastric pain.
  • [MeSH-minor] Aged. Ampulla of Vater. Carcinoma / complications. Common Bile Duct Neoplasms / complications. Female. Humans. Male. Neoplasm Recurrence, Local. Pancreatic Neoplasms / complications. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936449.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Zhang XH, Gao YT, Rashid A, Deng J, Liu EJ, Wu K, Sun L, Cheng JR, Gridley G, Hsing AW: [Tea consumption and risk of biliary tract cancers and gallstone disease: a population-based case-control study in Shanghai, China]. Zhonghua Zhong Liu Za Zhi; 2005 Nov;27(11):667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A population-based case-control study was conducted in urban Shanghai from 1 June 1997 to 31 May 2001 involving interviews with 627 new cases of biliary tract cancers (including 368 cases of gallbladder cancer, 191 cases of extrahepatic bile duct cancer and 68 cases of cancer of the ampulla of Vater) aged 35 to 74 years and 959 population controls frequency-matched to cases by gender and age in five-year group.
  • RESULTS: Compared with tea non-drinkers, current tea consumption was inversely associated with risk of gallbladder cancer, extrahepatic bile duct cancer and gallstone disease among females with OR of 0.57 (95% CI: 0.34-0.96), 0.53 (95% CI: 0.27-1.03) and 0.71 (95% CI: 0.51-0.99), respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438888.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Protective Agents; 0 / Tea
  •  go-up   go-down


17. Woo SM, Ryu JK, Lee SH, Lee WJ, Hwang JH, Yoo JW, Park JK, Kang GH, Kim YT, Yoon YB: Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. J Gastroenterol Hepatol; 2009 Jan;24(1):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer.
  • BACKGROUND AND AIM: Although endoscopic papillectomy has been attempted in early stage ampullary cancer (pTis, T1), its curative role and indications remain uncertain.
  • METHODS: We performed a retrospective analysis of clinical and histopathological data of 216 patients with ampullary cancer between 1991 and 2006.
  • Cases with early stage ampullary cancer of less than 2 cm with a well-differentiated histology and no angiolymphatic invasion (n = 13) showed no lymph node metastasis and no recurrence during a median follow up of 35.9 months.
  • CONCLUSION: Endoscopic papillectomy can be adopted as a viable alternative to surgery in patients with early stage ampullary cancer of less than 2 cm in size and with a well-differentiated histology.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Digestive System
  • [MeSH-minor] Cell Differentiation. Feasibility Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Patient Selection. Proportional Hazards Models. Recurrence. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032444.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. Lehwald N, Cupisti K, Baldus SE, Kröpil P, Schulte Am Esch J 2nd, Eisenberger CF, Knoefel WT: Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series. J Med Case Rep; 2010;4:402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series.
  • INTRODUCTION: The standard operation for carcinoma of the pancreatic head is a partial pancreaticoduodenectomy.
  • Histology showed an adenomyoma of the ampulla.
  • Pathology showed an undifferentiated carcinoma, sarcomatoid variant.
  • Adenomyoma of the bile duct or ampullary region is a very unusual, benign, localized lesion characterized by adenomyomatous hyperplasia.
  • Undifferentiated carcinoma, sarcomatoid variant, is an aggressive tumor and is characterized by spindle cells.
  • As the lesions were suspicious for carcinoma, partial pancreaticoduodenectomy was justified in all three patients.
  • The histologic diagnosis after partial pancreaticoduodenectomy may differ from the preoperative and intraoperative findings.
  • These cases demonstrate that a definitive diagnosis may only be obtained by a pathologic examination of the surgical specimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):530-6 [12808057.001]
  • [Cites] Surg Today. 2008;38(1):85-9 [18085373.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Pancreas. 2005 Oct;31(3):291-2 [16163064.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):547-50 [7550871.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Am J Obstet Gynecol. 1983 Feb 1;145(3):355-9 [6824025.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • (PMID = 21143956.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016302
  •  go-up   go-down


19. Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH, Schneider PM: Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol; 2006 Jan 21;12(3):437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.
  • AIM: We examined quantitative mRNA expression of growth factor receptors (c-erbB-1, c-erbB-2) and the anti-apoptosis gene survivin known to be regulated in pancreatic adenocarcinomas and compared the expression pattern with that in carcinomas of the papilla of Vater.
  • METHODS: Quantitative real-time reverse transcriptase-PCR (QRT-PCR, Taqman) was performed to analyze mRNA expression levels of c-erbB-1, c-erbB-2 and survivin in normal and corresponding tumor samples of 31 pancreatic adenocarcinomas and 8 cancers of the papilla of Vater.
  • RESULTS: The overall median mRNA expression of survivin was significantly increased in both adenocarcinoma of the pancreas (P<0.01) and papilla of Vater (P<0.008) compared with uninvolved normal control tissue.
  • In pancreatic cancer, expression of c-erbB-1 was significantly decreased compared with the normal pancreatic tissue (P<0.03), whereas in the cancer of the papilla of Vater expression of c-erbB-2 was significantly downregulated (P<0.05) compared with the paired normal samples.
  • CONCLUSION: The common anti-apoptosis gene survivin is overexpressed both in the cancer of the papilla of Vater and pancreas.
  • In contrast, the growth factor receptor genes c-erbB-1 and c-erbB-2 are differentially regulated in both tumor entities adding further evidence that pancreatic cancer is biologically different from the cancer of papilla of Vater.
  • [MeSH-major] Adenocarcinoma / metabolism. Ampulla of Vater. Common Bile Duct Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / genetics. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5 [10615931.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1241-6 [15870949.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):103-6 [10853025.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Lab Invest. 1999 Nov;79(11):1327-33 [10576203.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):677-85 [11455000.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):496-9 [11586103.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):1-23 [11719025.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Med Electron Microsc. 2001 Dec;34(4):207-12 [11956993.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Stat Methods Med Res. 2002 Jun;11(3):247-74 [12094758.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1593-7 [12168842.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Pediatr Dev Pathol. 2003 Sep-Oct;6(5):392-7 [14708732.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3922-9 [15004200.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):334-7 [15086152.001]
  • [Cites] Pancreas. 2004 Jul;29(1):e1-8 [15211117.001]
  • [Cites] Surgery. 2004 Aug;136(2):443-8 [15300213.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2759-61 [15309737.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Radiology. 1973 Nov;109(2):297-303 [4742316.001]
  • [Cites] Ann R Coll Surg Engl. 1985 May;67(3):139-43 [2988399.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2973-82 [2342466.001]
  • [Cites] J Pathol. 1990 Jul;161(3):195-200 [2202801.001]
  • [Cites] J Pathol. 1991 Feb;163(2):111-6 [1707959.001]
  • [Cites] Prog Growth Factor Res. 1992;4(1):1-24 [1355372.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):418-25 [7901825.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):786-92 [8206673.001]
  • [Cites] Cell. 1994 Jul 15;78(1):5-8 [8033211.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):392-6 [7637957.001]
  • [Cites] Int J Pancreatol. 1995 Feb;17(1):15-21 [8568330.001]
  • [Cites] J Urol. 1996 Jan;155(1):321-6 [7490879.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Genome Res. 1996 Oct;6(10):995-1001 [8908519.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):30-5 [9066744.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3841-7 [9427790.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):17-31 [10638554.001]
  • (PMID = 16489645.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC4066064
  •  go-up   go-down


20. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol; 2010 Feb 27;2(2):58-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, locoregional extension of these tumors is usually advanced with intrahepatic and lymph-node metastases at the time of diagnosis.
  • Only a small number of ICC cases, accompanied with ECC, gall bladder carcinoma, and ampullary carcinoma, have been reported in the studies of chemotherapy due to the rarity of the disease.
  • However, in some reports, significant anti-cancer effects were achieved with a response rate of up to 40% and a median survival of one year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160974.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2998957
  • [Keywords] NOTNLM ; Chemotherapy / Intrahepatic cholangiocarcinoma / Surgery
  •  go-up   go-down


21. Sa Cunha A, Larroudé D, Laurent C, Rault A, Collet D, Masson B: [Value of surgical ampullectomy in the management of benign ampullary tumors]. Ann Chir; 2005 Jan;130(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of surgical ampullectomy in the management of benign ampullary tumors].
  • [Transliterated title] Intérêt de l'ampullectomie chirurgicale dans la prise en charge des lésions bénignes de l'ampoule de Vater.
  • AIM OF THE STUDY: To report the results of transduodenal excision (TDE) for tumors of the ampulla of Vater.
  • PATIENTS AND METHODS: From 1998 to 2003, 10 patients underwent a transduodenal excision for presumed benign tumors of the ampulla of Vater.
  • Patient with an invasive cancer developed recurrence.
  • CONCLUSION: Transduodenal excision is safe and effective treatment for benign ampullary tumors.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664374.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Yoshizumi T, Shimada M, Soejima Y, Terashi T, Taketomi A, Maehara Y: Successful pylorus-preserving pancreaticoduodenectomy for a patient with carcinoma of the papilla Vater two years after living donor liver transplantation. Hepatogastroenterology; 2007 Apr-May;54(75):941-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pylorus-preserving pancreaticoduodenectomy for a patient with carcinoma of the papilla Vater two years after living donor liver transplantation.
  • For this reason, recurrent primary disease and/or de novo malignancy regarded as chronic immunosuppressant have been paid a great deal of attention.
  • Even pancreas cancer after liver transplantation is extremely rare and has never been successfully treated.
  • Furthermore, cancer of the papilla Vater, which is less frequent than pancreas cancer after liver transplantation has not been reported as yet.
  • In this paper we discuss the first case of cancer of the papilla Vater, which was successfully treated by pylorus-preserving pancreaticoduodenectomy two years after a living related liver transplantation using a left lobe.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods. Pylorus / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591098.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Chong VH, Telisinghe PU, Yapp SK, Jalihal A: Biliary strictures secondary to tuberculosis and early ampullary carcinoma. Singapore Med J; 2009 Mar;50(3):e94-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary strictures secondary to tuberculosis and early ampullary carcinoma.
  • Malignancies are important causes and are often unresectable at the time of diagnosis.
  • We report a 67-year-old man with unexpected findings of obstructive jaundice secondary to biliary TB and an early ampullary tumour.
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Biliary Tract Surgical Procedures. Constriction, Pathologic / pathology. Humans. Male. Risk Factors

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352560.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


24. Warnick P, Bahra M, Andreou A, Neuhaus P, Glanemann M: [Second-look operation in pancreatic carcinoma previously assessed as unresectable]. Zentralbl Chir; 2010 Feb;135(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second-look operation in pancreatic carcinoma previously assessed as unresectable].
  • BACKGROUND: The only curative therapy for patients with pancreatic carcinoma consists of -complete surgical tumour removal.
  • PATIENTS AND METHODS: We report herein on 17 patients who were judged during exploratory laparotomy elsewhere to suffer from non-resectable pancreatic cancer and who underwent a second-look operation after referral to our hospital.
  • The classic Kausch-Whipple operation was performed in 4, pylorus-preserving pancreaticoduodenectomy in 5, and left pancreatic -resection in another 4 patients.
  • Mean survival in patients after tumour resection was increased, reach-ing 17.6 months compared to 6.5 months in patients with non-resectable pancreatic cancer.
  • Thus, complex visceral operations like pancreatic carcinoma resection should preferably be performed in high-volume centres exclusively.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma, Pancreatic Ductal / surgery. Common Bile Duct Neoplasms / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Germany. Hospitals, General / statistics & numerical data. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pancreas / pathology. Pancreas / surgery. Prognosis. Referral and Consultation / statistics & numerical data. Reoperation / statistics & numerical data. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart, New York.
  • (PMID = 20162503.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT: Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg; 2006 Sep-Oct;10(8):1106-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between July 1994 and December 2004, 222 PD (78% pylorus preserving, 19% Whipple, and 3% total pancreatectomy) were performed for malignant disease.
  • Long-term survival was analyzed in 165 patients with pancreatic (n = 110), ampullary (n = 33), or distal bile (n = 22) duct cancer using univariate (log-rank) and multivariate (Cox regression) methods.
  • Five-year survival rates were 15% in cancer of the pancreatic head, 22% in ampullary cancer, and 24% in distal bile duct cancer (P = 0.02).
  • Univariate survival analysis of the 110 patients with cancer of the pancreatic head revealed that a histologically undifferentiated tumor (P = 0.05) and positive resection margins (P = 0.02) were associated with a poorer survival.
  • In case of tumor adherence or infiltration, combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection.
  • [MeSH-major] Mesenteric Veins / pathology. Mesenteric Veins / surgery. Pancreatic Neoplasms. Pancreaticoduodenectomy / methods. Portal Vein / pathology. Portal Vein / surgery. Vascular Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity / trends. Neoplasm Invasiveness. Postoperative Period. Prospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1080-6; discussion 1086-7 [16269378.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] J Vasc Interv Radiol. 2002 Aug;13(8):805-14 [12171984.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Pancreas. 2004 Apr;28(3):289-92 [15084973.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Chirurg. 2000 Jul;71(7):803-7 [10986602.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1089-95 [14675720.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1191-204; discussion 1204-6 [16332474.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] World J Surg. 1999 Sep;23(9):926-9 [10449822.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):201-8 [14769305.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):711-8 [8526577.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] J Gastrointest Surg. 2003 Feb;7(2):209-19 [12600445.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9 [8813262.001]
  • (PMID = 16966029.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


26. Chiche L, Alkofer B, Parienti JJ, Rouleau V, Salamé E, Samama G, Segol P: Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater. HPB (Oxford); 2007;9(2):140-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater.
  • BACKGROUND: The prognosis for carcinoma of the ampulla of Vater (CAV) is better than for pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] HPB Surg. 1998;11(1):1-11 [9830575.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2429-33 [10522012.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3274-5 [10626200.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):247-8 [11941966.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1116-9 [12143216.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1275-7 [15362731.001]
  • [Cites] Surgery. 2004 Nov;136(5):994-1002 [15523392.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1717-20 [2208026.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):632-7 [7487210.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):102-6; discussion 106-7 [7740792.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):95-100 [8098633.001]
  • [Cites] Surg Gynecol Obstet. 1993 Oct;177(4):366-70 [8211580.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Eur J Surg. 1996 Jun;162(6):477-81 [8817225.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Jul;79(4):259-63 [9244068.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1399-401 [9361598.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):600-3; discussion 603-4 [9409581.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Korean Med Sci. 1999 Apr;14(2):220-2 [10331573.001]
  • (PMID = 18333130.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020781
  •  go-up   go-down


27. Winter JM, Cameron JL, Lillemoe KD, Campbell KA, Chang D, Riall TS, Coleman J, Sauter PK, Canto M, Hruban RH, Schulick RD, Choti MA, Yeo CJ: Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg; 2006 May;243(5):673-80; discussion 680-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis.
  • BACKGROUND: While incidental masses in certain organs have received particular attention, periampullary and pancreatic incidentalomas (PIs) remain poorly characterized.
  • A total of 118 patients (6% of all PDs) presented with an incidental finding of a periampullary or pancreatic mass.
  • RESULTS: Thirty-one percent of the PI patients (n = 37) had malignant disease (versus 76% of the NI patients, P < 0.001), 47% (n = 55) had premalignant disease, and the remaining 22% (n = 26) had little or no risk for malignant progression.
  • The 3 most common diagnoses in the PI group were IPMN without invasive cancer (30%), cystadenoma (17%), and pancreatic ductal adenocarcinoma (10%).
  • The PI group had a higher overall complication rate (55% versus 43%, P = 0.02), due in part to a significantly increased rate of pancreatic fistulas (18.4% PI versus 8.5% NI, P < 0.001).
  • Patients in the PI group with malignant disease had a superior long-term survival (median, 30 months, P = 0.01) compared with patients in the NI group with malignant disease (median, 21 months).
  • CONCLUSIONS: Incidentally discovered periampullary and pancreatic masses comprise a substantial proportion of patients undergoing PD.
  • Roughly three fourths of these lesions are malignant or premalignant, and amenable to curative resection.
  • Resected malignant PIs have favorable pathologic features as compared with resected malignant NIs, and resection of these early lesions in asymptomatic individuals is associated with improved survival, compared with patients with symptomatic disease.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis


28. Noda T, Ohigashi H, Ishikawa O, Eguchi H, Yamada T, Sasaki Y, Yano M, Imaoka S: Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers. Ann Surg; 2007 Nov;246(5):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers.
  • OBJECTIVE: To evaluate the prognostic benefit of postoperative liver perfusion chemotherapy (LPC) in patients who undergo curative resection of duodenal and ampullary cancers.
  • SUMMARY BACKGROUND DATA: Both nodal involvement and pancreatic invasion are poor prognostic indicators after curative resection of ampullary or duodenal cancers due to high incidences of liver metastasis.
  • METHODS: During the period of 1990 to 2005, 72 consecutive patients successfully underwent curative (R0) resection of duodenal or ampullary carcinomas at our institution, The Osaka Medical Center for Cancer and Cardiovascular Diseases.
  • Of these 72 patients, 38 were found to have positive nodal involvement and/or pancreatic invasion based on an intraoperative inspection, and of these, 28 were deemed to be suitable candidates for intraoperative catheterization: 1 catheter was placed into the gastroduodenal artery; another into the portal vein (group A).
  • Postoperative histopathology was later performed to get a more accurate picture regarding the degree of nodal involvement and/or pancreatic invasion: In group A, 21 patients (group A1) proved positive for nodal and/or pancreatic invasion whereas 7 patients (group A2) proved negative; and in group B, 16 patients proved positive (group B1) whereas 28 proved negative (group B2).
  • Although group A displayed higher incidences of nodal involvement and pancreatic invasion, the 5-year survival rates for the 2 groups varied only slightly.
  • CONCLUSION: Through this research, both nodal involvement and pancreatic invasion were confirmed to be reliable predictors of liver metastasis after curative resection of ampullary and duodenal cancers.
  • [MeSH-major] Ampulla of Vater. Antimetabolites, Antineoplastic / administration & dosage. Common Bile Duct Neoplasms / therapy. Duodenal Neoplasms / therapy. Fluorouracil / administration & dosage. Liver Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968172.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Peng SY, Hong DF, Liu YB, Tan ZJ, Li JT, Tao F: [Binding pancreaticogastrostomy]. Zhonghua Wai Ke Za Zhi; 2009 Jan 15;47(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 2008 to October 2008, 15 patients were performed with BPG, included pancreatic head cancer in 7 cases, duodenal adenocarcinoma in 2 cases,mass-type chronic pancreatitis with pancreatolithiasis in 1 case, ampullary carcinoma in 1 case, gallbladder cancer in 1 case, islet cell tumor in 1 case and cholangiocarcinoma in 2 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563012.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Louvet C, Tournigand C: Time to move to targeted drugs in biliary tract cancer? Onkologie; 2010;33(1-2):10-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to move to targeted drugs in biliary tract cancer?
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Common Bile Duct Neoplasms / drug therapy. Drug Delivery Systems / methods. Gallbladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2010;33(1-2):45-7 [20164661.001]
  • (PMID = 20164655.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Singh A, Singh T, Chaudhary A: Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. JOP; 2010;11(5):434-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: There is limited information available about the feasibility and benefits of synchronous resection of liver metastases in patients with pancreatic and periampullary cancer undergoing pancreaticoduodenectomy.
  • PATIENTS: Two-hundred and thirty patients underwent pancreaticoduodenectomy for pancreatic and periampullary cancer in our unit between September 2003 and September 2009.
  • CONCLUSIONS: In patients with resectable pancreatic and periampullary cancer, the resection of a solitary liver metastasis can safely be performed together with a pancreaticoduodenectomy; however, its impact on improving survival has yet to be proven.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ampulla of Vater / pathology. Ampulla of Vater / surgery. Female. Hepatectomy / methods. Humans. Intraoperative Period. Male. Middle Aged. Retrospective Studies. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2011 Jan;12(1):68-9; author reply 71 [21206108.001]
  • (PMID = 20818110.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH: Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol; 2006;1:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other sites.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Capecitabine. Dose-Response Relationship, Radiation. Drug Administration Schedule. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / radiotherapy. Humans. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1337-45 [10715306.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):349-58 [11818199.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3983-91 [12351595.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9 [15145162.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1019-24 [15305186.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1325-30 [15993549.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8679-87 [16314628.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1145-51 [16505434.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • (PMID = 17062148.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1634749
  • [General-notes] NLM/ Original DateCompleted: 20070808
  •  go-up   go-down


33. Sakata E, Shirai Y, Yokoyama N, Wakai T, Sakata J, Hatakeyama K: Clinical significance of lymph node micrometastasis in ampullary carcinoma. World J Surg; 2006 Jun;30(6):985-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of lymph node micrometastasis in ampullary carcinoma.
  • BACKGROUND: This study aimed to clarify the clinical significance of lymph node micrometastasis in ampullary carcinoma.
  • MATERIALS AND METHODS: Pancreaticoduodenectomy with regional lymphadenectomy was performed for 50 consecutive patients with ampullary carcinoma.
  • CONCLUSIONS: Immunohistochemically detected lymph node micrometastasis indicates intensive lymphatic spread, and thus adversely affects the survival of patients with ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymph Node Excision. Lymph Nodes / chemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1984 Aug;50(2):193-7 [6380553.001]
  • [Cites] Surgery. 1996 Apr;119(4):397-402 [8644003.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):201-7 [12560778.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):769-78 [10091753.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Nov;122(5):900-6 [11689794.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):190-4 [8637205.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3853-6 [8033106.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1465-9 [10193935.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1717-20 [2208026.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):88-95 [8554990.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):858-66 [9731887.001]
  • [Cites] Histopathology. 1998 Mar;32(3):199-208 [9568504.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2105-13 [14601079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):1012-6 [9240155.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1244-9 [9788387.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):593-6; discussion 596-7 [2589595.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1069-76 [9070482.001]
  • [Cites] Surgery. 2001 Jun;129(6):704-13 [11391369.001]
  • [Cites] Aust N Z J Surg. 1993 Apr;63(4):256-62 [7906119.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):133-9 [11753052.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1595-600 [7520351.001]
  • [Cites] Surgery. 2000 Jan;127(1):32-9 [10660756.001]
  • (PMID = 16736326.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


34. Wu LH, Zhang W: [Prevention and treatment of complications after duodenopancreatectomy]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Apr;25(4):461-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinical data of 36 cases receiving duodenopancreatectomy during the last decade were analyzed, including 13 cases of ampullary carcinoma, 8 cases of carcinoma of the pancreas head, 8 cases of distal cholangiocarcinoma, and 7 cases of carcinoma of the duodenal papilla.
  • RESULTS: Complications occurred in 6 cases after duodenopancreatectomy including pancreatic fistula in 3 cases, bile duct fistula in 1 case, abdominal cavity hemorrhage in 1 case, and alimentary tract hemorrhage in 1 case, with an incidence rate of postoperative complications of 16.7%; and death occurred in 2 cases.
  • CONCLUSION: Adequate measures should be taken to reduce such complications as pancreatic fistula, bile duct fistula, abdominal cavity hemorrhage, alimentary tract hemorrhage and abdominal cavity infection, and these measures include nutritional support, careful operation in the surgery with adequate drainage, and careful observation and nursing after the surgery.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / prevention & control
  • [MeSH-minor] Adult. Aged. China / epidemiology. Common Bile Duct Neoplasms / surgery. Female. Humans. Male. Middle Aged. Pancreatic Fistula / epidemiology. Pancreatic Fistula / etiology. Pancreatic Fistula / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837657.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Hsu HP, Shan YS, Hsieh YH, Yang TM, Lin PW: Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc; 2007 Jun;106(6):432-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence.
  • BACKGROUND/PURPOSE: Ampullary cancer is one of the periampullary cancers with a better prognosis, but relapse still occurs early in some patients.
  • METHODS: Between January 1989 and March 2006, information was gathered on a total of 127 patients undergoing pancreaticoduodenectomy with regional lymphadenectomy for ampullary cancer at National Cheng Kung University Hospital and Tainan Municipal Hospital.
  • The early and late recurrence patients had higher levels of microscopically (R1) or macroscopically (R2) positive margin of resection and more advanced disease (advanced tumor stage, numbers of lymph nodes involved, lymph node status, pancreatic invasion and TNM stage) than the non-recurrence group.
  • After multivariate analysis, positive resection margin, pancreatic invasion and lymph node involvement were significant predictors for disease recurrence.
  • CONCLUSION: Positive resection margin, pancreatic invasion, and lymph node involvement were found to be predictors for disease recurrence and indicators for postoperative treatment.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588836.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


36. Sonoue H, Suda K, Nobukawa B, Abe H, Arakawa A, Hirai S, Matsumoto T: Does ampullary carcinoma arise from distended glands in the papilla of Vater? J Hepatobiliary Pancreat Surg; 2008;15(2):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does ampullary carcinoma arise from distended glands in the papilla of Vater?
  • BACKGROUND/PURPOSE: Glands near the surface of the papilla of Vater may become distended with mucus and become hyperplastic; that is, become distended.
  • METHODS: Twenty-nine pancreatoduodenectomized nontumorous duodenal papilla specimens from carcinoma of the pancreas and bile duct and 34 resected ampullary carcinoma specimens were studied histopathologically and immunohistochemically, using cytokeratins and mucin immunohistochemical features/phenotypes.
  • Immunopositivity for CK7, CK20, and MUC5AC was found in 25, 21, and 18 of the 34 specimens of ampullary carcinoma, respectively.
  • CONCLUSIONS: Although most ampullary carcinomas arise from the duodenal mucosa or intra-ampullary mucosa, both CK7-positive and MUC5AC-positive or only MUC5ACpositive ampullary carcinomas may arise from the distended glands.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / metabolism. Common Bile Duct Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392709.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Keratin-7; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


37. Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N: A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology; 2010;78(5-6):356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.
  • PURPOSE: To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer.
  • CONCLUSION: The combination of oxaliplatin and irinotecan has a modest antitumor activity with manageable toxicity as first-line treatment in metastatic cancer of the biliary tract and therefore it cannot be recommended as front-line treatment for unresectable biliary tract cancer.
  • [MeSH-minor] Adult. Aged. Ampulla of Vater / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / pathology. Female. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright ©2010 S. Karger AG, Basel.
  • (PMID = 20798557.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


38. Chang SK, Liang WT, Thamboo TP: Inflammatory pseudotumour arising from periampullary carcinoid: a "cancer-like" tumour in a "fake" tumour. Singapore Med J; 2009 Mar;50(3):e100-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumour arising from periampullary carcinoid: a "cancer-like" tumour in a "fake" tumour.
  • We present a 52-year-old Chinese woman with a carcinoid at the ampulla of Vater, a site far less common than other areas of the gastrointestinal tract.
  • Preoperative imaging showed a pancreatic mass with displacement and possible invasion of the portal vein associated with peripancreatic nodal enlargement.
  • An intraoperative biopsy of the enlarged nodes was negative for malignancy and postoperative histology of the large pancreatic mass yielded a surprising finding of a carcinoid tumour at the ampulla of Vater with a large inflammatory pancreatic mass adherent to the portal vein.
  • This is an uncommon case associated with "pseudotumour pancreatitis", causing biliary and pancreatic duct obstruction mimicking a large tumour in the head of the pancreas.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoid Tumor / complications. Gallbladder Neoplasms / complications. Granuloma, Plasma Cell / etiology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352550.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


39. Sawaki A, Mizuno N, Hoki N, Ishikawa H, Takagi T, Yamao K: [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
  • We report a case of recurrent carcinoma of the ampulla of Vater with multiple lung and abdominal lymph node metastases that well responded to S-1, an oral fluoropyrimidine.
  • A 56-years-old woman underwent a pylorus-preserving pancreaticoduodenectomy for carcinoma of the ampulla of Vater in October 2003.
  • S-1 might be an effective and safe agent for carcinoma of the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Antimetabolites, Antineoplastic / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / surgery. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


40. Haddad LB, Scatton O, Randone B, Andraus W, Massault PP, Dousset B, Soubrane O: Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice. HPB (Oxford); 2009 May;11(3):203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice.
  • BACKGROUND: A pancreatic fistula (PF) is the most common complication after pancreaticoduodenectomy (PD), and its reported incidence varies from 2% to 28%.
  • The main indications for PD were pancreatic duct carcinoma in 52 patients (44.5%), ampullary carcinoma or adenoma in 18 (15.4%) and islet cell tumour in 11 (9.4%).
  • The medium delay between the pancreatic resection and reoperation was 10 days (range, 3-32 days).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2004 Jan;139(1):16-9 [14718268.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] World J Surg. 2003 Jun;27(6):709-14 [12732998.001]
  • [Cites] Arch Surg. 2006 Jun;141(6):574-9; discussion 579-80 [16785358.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):767-71, discussion 771-3 [16327486.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1117-23 [15931656.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):849-54; discussion 854-6 [16172293.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] World J Surg. 2005 Feb;29(2):212-6 [15654661.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):951-9 [15585382.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):766-72; discussion 772-4 [15531229.001]
  • [Cites] World J Surg. 1999 Feb;23(2):164-71; discussion 171-2 [9880426.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):18-24 [9208956.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):176-9 [8689156.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1270-3 [7552016.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):265-9 [8156354.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):295-8 [7524375.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):521-4 [1350387.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):125-30; discussion 130-1 [1733360.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):39-47 [3276272.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):198-203 [15275873.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315 [14662530.001]
  • [Cites] J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565 [12691930.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):57-65 [12496531.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1245-51 [12296891.001]
  • [Cites] Dig Surg. 2001;18(6):453-7; discussion 458 [11799295.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):117-20 [11044525.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):419-29 [10973392.001]
  • [Cites] J Gastrointest Surg. 2003 Jul-Aug;7(5):672-82 [12850681.001]
  • (PMID = 19590648.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697888
  • [Keywords] NOTNLM ; pancreatic fistula / pancreatic resection / pancreaticoduodenectomy / postoperative complications
  •  go-up   go-down


41. Sun JH, Chao M, Zhang SZ, Zhang GQ, Li B, Wu JJ: Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater. World J Gastroenterol; 2008 Aug 7;14(29):4709-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater.
  • Small cell neuroendocrine carcinoma of the ampulla of Vater is extremely rare and different from the common ampullary adenocarcinoma.
  • The ampullary adenoma is also a rare neoplasm and has the potential to develop an adenocarcinoma.
  • We herein describe an unusual case of a small cell neuroendocrine carcinoma associated with a villous adenoma in the ampulla of Vater with emphasis on computed tomography (CT) and histopathological findings.
  • [MeSH-major] Adenoma, Villous / complications. Ampulla of Vater. Carcinoma, Neuroendocrine / complications. Common Bile Duct Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):870-6 [12024143.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):221-3 [12562240.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):232-8 [15368106.001]
  • [Cites] J Natl Cancer Inst. 1981 Sep;67(3):607-12 [6268879.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(5):450-3 [17013721.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):703-13 [1696069.001]
  • [Cites] Gut. 1991 Dec;32(12):1558-61 [1773967.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1502-4 [1325273.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):56-60 [15747032.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Clin Gastroenterol. 1986 Apr;15(2):439-56 [3731520.001]
  • (PMID = 18698690.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738800
  •  go-up   go-down


42. Yamao K, Sawaki A, Takahashi K, Imaoka H, Ashida R, Mizuno N: EUS-guided choledochoduodenostomy for palliative biliary drainage in case of papillary obstruction: report of 2 cases. Gastrointest Endosc; 2006 Oct;64(4):663-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Ampulla of Vater / surgery. Choledochostomy / instrumentation. Cholestasis, Extrahepatic / surgery. Common Bile Duct Neoplasms / surgery. Endosonography / instrumentation. Palliative Care. Pancreatic Neoplasms / surgery. Stents
  • [MeSH-minor] Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde / instrumentation. Drainage / instrumentation. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996372.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Balachandran P, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK: Long-term survival and recurrence patterns in ampullary cancer. Pancreas; 2006 May;32(4):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and recurrence patterns in ampullary cancer.
  • OBJECTIVE: Ampullary cancers are associated with high resectability rates and good long-term survival.
  • METHODS: One hundred thirteen patients with ampullary cancer underwent pancreaticoduodenectomy between 1989 and 2000, with 48% morbidity and 8% mortality.
  • CONCLUSIONS: Lymph node metastasis and vascular invasion were 2 important factors, which adversely influenced survival in patients with ampullary cancer.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Survival Rate. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670621.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Zhang XM, Shen CY, Li W, Zhang XM: [Surgical treatment of tumor invading important vessel]. Zhonghua Wai Ke Za Zhi; 2007 Aug 1;45(15):1044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor involving thoraco-abdominal cavity was in one case with malignant neuroblastoma.
  • Tumor located in thoracic cavity were in 13 cases including IVC leiomyosarcoma in 2 cases, thymic carcinoma in 3 cases, malignant thymoma in 4 cases, malignant seminoma of superior mediastinum in 1 case, malignant lymphoma in 1 case, lung cancer in 2 cases.
  • The tumor located in abdominal cavity were in 24 cases including renal carcinoma with tumor thrombi in 11 cases, inflammatory pseudotumor of retro-peritoneum in 4 cases, malignant fibrous histiocytoma of retro-peritoneum in 1 case, non-Hodgkin's disease of retro-peritoneum in 1 case, lymph metastasis of retro-peritoneum in 2 cases, paraganglion tumor of the right adrenal gland in 1 case, ampullary carcinoma in 1 case, leiomyosarcoma of abdominal IVC in 1 case, leiomyosarcoma of pelvic cavity and IVC in 1 cases, fibrosarcoma of pelvic cavity in 1 case.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome. Vena Cava, Inferior / pathology. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005586.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Mizuno T, Ishizaki Y, Ogura K, Yoshimoto J, Kawasaki S: Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg; 2006 Feb;93(2):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater.
  • BACKGROUND: The aim of this study was to assess the impact of immunohistochemically identified lymph node metastasis on survival in patients with carcinoma of the ampulla of Vater.
  • METHODS: Three hundred and twenty-six regional lymph nodes dissected from pancreatoduodenectomy specimens from 25 patients with ampulla of Vater carcinoma were immunostained with anticytokeratin antibody (CAM 5.2).
  • CONCLUSION: Immunostaining of dissected lymph nodes adds additional information to data obtained by conventional haematoxylin and eosin staining when determining the prognosis of patients with carcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 16363020.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A: Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur J Histochem; 2010;54(3):e38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
  • The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer.
  • Aim of the present study is to evaluate the variations of hENT1 expression in ampullary carcinomas and to correlate such variations with histological subtypes and clinicopathological parameters.
  • Forty-one ampullary carcinomas were histologically classified into intestinal, pancreaticobiliary and unusual types. hENT1 and Ki67 expression were evaluated by immunohistochemistry, and apoptotic cells were identified by the terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate biotin nick end labelling (TUNEL) method. hENT1 overexpression was detected in 63.4% ampullary carcinomas.
  • Our results on hENT1 expression suggest that classification of ampullary carcinoma by morphological subtypes may represent an additional tool in prospective clinical trials aimed at examining treatment efficacy; in addition, data obtained from Ki67 and TUNEL suggest a key role of hENT1 in tumour growth of ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Carcinoma / metabolism. Equilibrative Nucleoside Transporter 1 / metabolism. Intestinal Neoplasms / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2128-34 [10445539.001]
  • [Cites] Mol Med Today. 1999 May;5(5):216-24 [10322314.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):229-35 [8764931.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):173-7 [8567113.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1394-402 [3422832.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6956-61 [15501974.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):558-64 [15529184.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):941-5 [12209675.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):236-42 [11920781.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):110-6 [11801546.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):187-95 [18992248.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):724-8 [18187485.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jul;293(1):F200-11 [17409283.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Mar;61(3):230-42 [17157524.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):334-40 [16906389.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):711-6 [16341310.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):363-70 [15923058.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3784-9 [15897577.001]
  • (PMID = 20839414.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Equilibrative Nucleoside Transporter 1
  • [Other-IDs] NLM/ PMC3167316
  •  go-up   go-down


47. Palanivelu C, Jani K, Senthilnathan P, Parthasarathi R, Rajapandian S, Madhankumar MV: Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg; 2007 Aug;205(2):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The procedure could be completed laparoscopically with tumor-free margins in all patients, including patients with ampullary carcinoma (n = 24), pancreatic cystadenocarcinoma (n = 4), pancreatic head adenocarcinoma (n = 9), low common bile duct cancer (n = 3), and two patients with chronic pancreatitis with a suspicious mass lesion in the head of pancreas.
  • Five-year actuarial survival rates for all patients with malignancy, ampullary adenocarcinoma, pancreatic cystadenocarcinoma, pancreatic head adenocarcinoma, and common bile duct adenocarcinoma are 32%, 30.7%, 33.3%, 19.1%, and 50%, respectively.
  • Localized malignant lesions, irrespective of histopathology, are particularly amenable to this approach.
  • [MeSH-major] Duodenal Neoplasms / surgery. Laparoscopy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Berberat PO, Künzli BM, Gulbinas A, Ramanauskas T, Kleeff J, Müller MW, Wagner M, Friess H, Büchler MW: An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol; 2009 Feb;35(2):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-pancreatic periampullary carcinoma such as ampullary carcinoma (AmpCA), distal cholangiocellular carcinoma (CholCA) and duodenal carcinoma (DuoCA) have a better prognosis than pancreatic head adenocarcinoma (PanCA).
  • This study describes the outcome and parameters, which predict survival of non-pancreatic periampullary carcinoma after resection.
  • METHODS AND PATIENTS: Data from 148 consecutive patients with non-pancreatic periampullary carcinomas were recorded prospectively between 1993 and 2005 and analyzed using univariate and multivariate models.
  • RESULTS: One hundred thirty-three of 148 (90%) patients were resected for histologically proven non-pancreatic periampullary carcinomas.
  • CONCLUSION: Only T1/T2 ampullary carcinomas have a good prognosis, whereas T3/T4 ampullary tumors show aggressiveness similar to that of pancreatic head adenocarcinomas.
  • [MeSH-major] Ampulla of Vater. Biliary Tract Surgical Procedures / methods. Carcinoma / surgery. Clinical Audit / methods. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343082.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


49. Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR: Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford); 2010 Aug;12(6):418-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with histologically proven BTCs, including cholangiocarcinoma or gallbladder and ampullary carcinomas, were treated with a maximum of nine cycles of intravenous (i.v.) gemcitabine at 1000 mg/m(2) over 30 min on days 1 and 8 with i.v. carboplatin dosed at an area-under-the-curve (AUC) of 5 over 60 min on day 1 of a 21-day cycle.
  • RESULTS: A total of 48 patients with advanced BTCs (35 cholangiocarcinoma, 12 gallbladder and 1 ampullary cancer) were enrolled.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1833-8 [11576836.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4089-91 [11600613.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer. 1974 Jan;33(1):193-7 [4272473.001]
  • [Cites] Br J Surg. 1974 Feb;61(2):98-100 [4361236.001]
  • [Cites] Ann Surg. 1982 Mar;195(3):270-3 [7059239.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):965-9 [6235908.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):120-5 [2829760.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):871-7; discussion 877-9 [8393652.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):607-9 [8363992.001]
  • [Cites] J Surg Oncol. 1994 Apr;55(4):239-45 [8159005.001]
  • [Cites] Am J Clin Oncol. 1994 Jun;17(3):223-6 [8192106.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):931-4 [9625849.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1030-4 [15990005.001]
  • [Cites] BMC Cancer. 2005;5:61 [15949047.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):134-41 [17207911.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):847-57 [17551145.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3702-8 [18669455.001]
  • [Cites] Clin Breast Cancer. 2008 Oct;8(5):425-31 [18952556.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):371-7 [19142638.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 20662793.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00660140
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC3028583
  •  go-up   go-down


50. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC: Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol; 2005 Feb;20(2):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
  • It was hypothesized that uPA would be overexpressed in highly metastatic pancreatic cancer.
  • The aims of this study were to analyze uPA mRNA expression in pancreatic cancer and to correlate this to the expression of uPA protein and to the stage of the disease.
  • METHODS: Twenty-one pancreatic adenocarcinoma, six ampullary carcinoma and 10 benign mucinous cystadenoma samples, all with adjacent normal tissue, were collected. uPA mRNA was measured using real-time quantitative reverse transcription polymerase chain reaction.
  • Localization of uPA within normal and pancreatic tumor sections was subsequently confirmed using immunohistochemistry.
  • RESULTS: The median and range of the ratios of uPA mRNA measures between tumor tissue and non-involved pancreatic tissue was 17.1 (1.4-653.6) for pancreatic adenocarcinoma (P < 0.001), 3.9 (0.7-7.7) for ampullary carcinoma (P = 0.055) and 1.9 (0.6-5.9) for mucinous cystadenoma tissue (P = 0.052).
  • Immunohistochemistry confirmed that uPA protein was more prevalent in pancreatic adenocarcinoma tissue than in normal tissue and that it was membrane-bound. uPA mRNA expression was significantly associated with poorly differentiated pancreatic cancers (P < 0.05) and positively associated with tumor stage.
  • CONCLUSIONS: These observations suggest that significant overexpression of uPA correlates closely to the rapid progression and invasiveness of pancreatic cancer and that uPA may provide a future therapeutic target for pancreatic cancer treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Pancreatic Neoplasms / genetics. Urokinase-Type Plasminogen Activator / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 15683429.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


51. Jin SG, Chen ZY, Yan LN, Zeng Y, Huang W, Xu N: A rare case of periampullary carcinoma with ectopic ending of Vater's ampulla. World J Gastroenterol; 2009 Oct 7;15(37):4729-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of periampullary carcinoma with ectopic ending of Vater's ampulla.
  • Magnetic resonance imaging and magnetic resonance cholangiopancreatography (MRCP) showed the ectopic hepatopancreatic ampulla draining into the fourth part of the duodenum adjacent to the duodenojejunal flexure; the irregular morphology of the duodenojejunal flexure likely due to a soft tissue mass.
  • Laparotomy confirmed the presence of the abnormal ampulla of Vater located at the fourth part of the duodenum and a soft tissue tumor about 6 cm x 5 cm x 5 cm with a peduncle adjoining the ampulla.
  • Periampullary carcinoma with ectopic ending of the Vater's ampulla into the fourth part of the duodenum is rather rare.
  • It is worth mentioning that MRCP is useful for demonstrating anomalies and anatomic variants of the biliary tract system and pancreatic duct.
  • [MeSH-major] Adenoma, Villous / diagnosis. Ampulla of Vater / abnormalities. Duodenal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Natl Cancer Inst Monogr. 1964 Apr;13:51-65 [14143237.001]
  • [Cites] Anat Rec. 1961 Jan;139:59-68 [14025604.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):371-3 [16111954.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1268-70 [17451212.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2007 Oct;17(5):434-7 [18049409.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1251-4 [10541098.001]
  • [Cites] J Comput Assist Tomogr. 2002 Jan-Feb;26(1):141-2 [11801920.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Aug;12(4):273-6; discussion 276-8 [12193823.001]
  • [Cites] Ann Chir. 2004 Jul-Aug;129(6-7):381-6 [15297231.001]
  • [Cites] Ann Surg. 1976 Nov;184(5):626-32 [984933.001]
  • [Cites] Arch Surg. 1985 Sep;120(9):1077-9 [2411244.001]
  • [Cites] Jpn J Med. 1988 Feb;27(1):79-82 [3367542.001]
  • [Cites] G E N. 1991 Apr-Jun;45(2):145-6 [1843939.001]
  • [Cites] Ann Gastroenterol Hepatol (Paris). 1996 Nov-Dec;31(6):346-8 [8920078.001]
  • [Cites] Surg Gynecol Obstet. 1958 Oct;107(4):447-56 [13580794.001]
  • [Cites] Folia Morphol (Warsz). 2005 Feb;64(1):51-3 [15832271.001]
  • (PMID = 19787838.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2754523
  •  go-up   go-down


52. Ohno T, Koguchi H, Miura A, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Tokuda Y, Sakakibara K: [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine]. Gan To Kagaku Ryoho; 2009 Jun;36(6):999-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
  • He was diagnosed as having advanced ampullary carcinoma(T4 N0 H1, Stage IV b).
  • This is a very instructive case for developing effective chemotherapy options to treat biliary tract cancers involving ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


53. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A: Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol; 2005 Feb;58(2):159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
  • BACKGROUND: There is a lack of data in the literature concerning the identification of potential prognostic factors in ampullary adenocarcinoma.
  • AIMS: To examine the prognostic significance of Bax, Bcl-2, and p53 protein expression and the apoptotic index in a large cohort of uniformly treated patients with radically resected ampullary cancer.
  • METHODS: All patients with a pathological diagnosis of ampullary cancer and radical resection were evaluated.
  • RESULTS: Thirty nine tumour specimens from patients with radically resected ampullary adenocarcinoma were studied.
  • CONCLUSIONS: These results provide evidence that apoptosis may be an important prognostic factor in patients with radically resected ampullary cancer.
  • This study is the first to assess the clinical usefulness of Bax expression in radically resected ampullary cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Ampulla of Vater. Common Bile Duct Neoplasms / chemistry. In Situ Nick-End Labeling / methods. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):528-32 [1537617.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):374-80 [10646891.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jan;12(1):75-9 [10656214.001]
  • [Cites] Gut. 2000 Jun;46(6):842-8 [10807898.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):344-50; discussion 350-1 [11524587.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1266-70 [11677943.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):637-44 [12359201.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):218-24 [12692419.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):336-41 [14645696.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Arch Surg. 1990 Jun;125(6):723-6 [2189376.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4828-31 [1324796.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4471-8 [7671262.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2583-90 [9704707.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Gut. 1998 Sep;43(3):414-21 [9863489.001]
  • [Cites] Mol Hum Reprod. 1998 Dec;4(12):1099-109 [9872359.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1841-7 [9815572.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1187-91 [10370689.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):100-5 [8606540.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14559-63 [8962091.001]
  • [Cites] Cell. 1997 Apr 18;89(2):175-84 [9108473.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11357-62 [9326614.001]
  • [Cites] Blood. 1997 Oct 15;90(8):3173-8 [9376600.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31482-8 [9395483.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7770-5 [9516487.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • (PMID = 15677536.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC1770581
  •  go-up   go-down


54. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol; 2005 Mar;31(2):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
  • AIM: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.
  • METHODS: Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases.
  • RESULTS: The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01).
  • CONCLUSION: The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Islet Cell / blood. Carcinoma, Islet Cell / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bilirubin / blood. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Sensitivity and Specificity. Statistics as Topic. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698733.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


55. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • We experienced a 68-year-old woman who presented with obstructive jaundice due to an ampullary mass 1.0 cm in diameter, detected by abdominal computed tomography and endoscopic examination.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Endosonography. Female. Follow-Up Studies. Humans. Middle Aged. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Dig Surg. 2005;22(5):377-9 [16432300.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):568-71 [8192567.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):121-3 [11154509.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y: Signet-ring cell carcinoma of the ampulla of Vater: report of a case. Surg Today; 2007;37(12):1110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the ampulla of Vater: report of a case.
  • Signet-ring cell carcinoma (SRCC) of the ampulla of Vater is uncommon, and only 13 cases have been previously described.
  • We herein report a rare case of a 43-year-old woman with SRCC in the ampulla of Vater.
  • Although this histologic type of cancer generally predicts a poor prognosis elsewhere in the gastrointestinal tract, the present patient has survived with no evidence of recurrence for 7.5 years.
  • She underwent a pancreaticoduodenectomy with an extended lymphadenectomy for ampullary carcinoma.
  • This neoplasm was classified as AcdbBi, 2.0 x 1.8 cm, ulcerative type, Panc(0), Du(2), T(2)N(0)M(-), Stage II according to the Japanese Classification on Cancer of the Biliary Tract.
  • Unfortunately, previous reports of ampullary SRCC have been limited to short-term follow-ups with a median period of only 12 months (range, 6-134 months), and long-term survival (more than 5 years) was only documented in two cases without lymph node metastasis (including the present case).
  • In conclusion, the experience gained in the present and previous cases suggests that long-term survival is possible following a curative resection in selected patients with ampullary SRCC without nodal involvement.
  • Due to the lack of sufficient evidence, additional reports are warranted to determine whether SRCC also portends a poor prognosis in patients with ampullary cancer.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Signet Ring Cell / pathology. Common Bile Duct Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1319-24 [15376179.001]
  • [Cites] Digestion. 1970;3(3):165-73 [4915587.001]
  • [Cites] Ann Clin Lab Sci. 2004 Autumn;34(4):471-5 [15648791.001]
  • [Cites] Am Surg. 2006 Feb;72(2):193-5 [16536256.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] J Formos Med Assoc. 2004 Oct;103(10):793-6 [15490032.001]
  • [Cites] JOP. 2004 Nov 10;5(6):495-7 [15536289.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1071-2 [2171451.001]
  • [Cites] Helv Chir Acta. 1994 Dec;60(6):987-90 [7876027.001]
  • [Cites] Indian J Gastroenterol. 2005 Sep-Oct;24(5):222-3 [16361773.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Fukuoka Igaku Zasshi. 2003 Jul;94(7):235-40 [14509231.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):561-3 [11995497.001]
  • [Cites] Rev Esp Enferm Dig. 1994 May;85(5):391-3 [8049111.001]
  • [Cites] Surg Today. 2003;33(6):467-9 [12768376.001]
  • [Cites] Am J Gastroenterol. 1982 Feb;77(2):111-4 [7072678.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Surg Oncol. 1994 Aug;3(4):221-7 [7834113.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):733 [12397285.001]
  • (PMID = 18030577.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


57. Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT: Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol; 2005 Apr 28;11(16):2456-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors of pancreatic leakage after pancreaticoduodenectomy.
  • AIM: To analyze the risk factors for pancreatic leakage after pancreaticoduodenectomy (PD) and to evaluate whether duct-to-mucosa pancreaticojejunostomy could reduce the risk of pancreatic leakage.
  • The primary diseases of the patients included pancreas cancer, ampullary cancer, bile duct cancer, islet cell cancer, duodenal cancer, chronic pancreatitis, pancreatic cystadenoma, and gastric cancer.
  • A duct-to-mucosa pancreaticojejunostomy was performed for patients with a hard pancreas and a dilated pancreatic duct, and a traditional end-to-end invagination pancreaticojejunostomy for patients with a soft pancreas and a non-dilated duct.
  • Seven preoperative and six intraoperative risk factors with the potential to affect the incidence of pancreatic leakage were analyzed with SPSS10.0 software.
  • Logistic regression was then used to determine the effect of multiple factors on pancreatic leakage.
  • RESULTS: Of the 62 patients, 10 (16.13%) were identified as having pancreatic leakage after operation.
  • The hospital mortality in this series was 4.84% (3/62), and the mortality associated with pancreatic fistula was 10% (1/10).
  • Sixteen cases underwent duct-to-mucosa pancreaticojejunostomy and 1 case (1/16, 6.25%) developed postoperative pancreatic leakage, 46 cases underwent invagination pancreaticojejunostomy and 9 cases (9/46, 19.6%) developed postoperative pancreatic leakage.
  • General risk factors including patient age, gender, history of jaundice, preoperative nutrition, pathological diagnosis and the length of postoperative stay were similar in the two groups.
  • There was no statistical difference in the incidence of pancreatic leakage between the patients who received the prophylactic use of octreotide after surgery and the patients who did not undergo somatostatin therapy.
  • Moreover, multivariate logistic regression analysis showed that none of the above factors seemed to be associated with pancreatic fistula.
  • Two intraoperative risk factors, pancreatic duct size and texture of the remnant pancreas, were found to be significantly associated with pancreatic leakage.
  • The incidence of pancreatic leakage was 4.88% in patients with a pancreatic duct size greater than or equal to 3 mm and was 38.1% in those with ducts smaller than 3 mm (P = 0.002).
  • The pancreatic leakage rate was 2.94% in patients with a hard pancreas and was 32.1% in those with a soft pancreas (P = 0.004).
  • The incidence of pancreatic leakage was 6.25% (1/16) in patients with duct-to-mucosa anastomosis, and was 19.6% (9/46) in those with traditional invagination anastomosis.
  • Although the difference of pancreatic leakage between the two groups was obvious, no statistical significance was found.
  • By further analyzing with multivariate logistic regression, both pancreatic duct size and texture of the remnant pancreas were demonstrated to be independent risk factors (P = 0.007 and 0.017, OR = 11.87 and 15.45).
  • Although anastomotic technique was not a significant factor, pancreatic leakage rate was much less in cases that underwent duct-to-mucosa pancreaticojejunostomy.
  • CONCLUSION: Pancreatic duct size and texture of the remnant pancreas are risk factors influencing pancreatic leakage after PD.
  • Duct-to-mucosa pancreaticojejunostomy, as a safe and useful anastomotic technique, can reduce pancreatic leakage rate after PD.
  • [MeSH-major] Intraoperative Complications / epidemiology. Pancreatic Diseases / epidemiology. Pancreatic Diseases / surgery. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Duodenum / surgery. Female. Humans. Male. Middle Aged. Pancreas / surgery. Pancreatic Ducts / surgery. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305634
  •  go-up   go-down


58. Tien YW, Yeh CC, Wang SP, Hu RH, Lee PH: Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms? J Gastrointest Surg; 2009 Sep;13(9):1666-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms?
  • BACKGROUND: Many specialists justify pancreaticoduodenectomy (PD) for pancreatic head neoplasms with suspected but unproven malignance (blind-PD).
  • Our aim in this study was to determine whether blind-PD is also justified for ampullary neoplasms.
  • METHODS: We retrospectively reviewed the records of all patients with presumed resectable ampullary neoplasms treated at the National Taiwan University Hospital from 1998 to 2008.
  • RESULTS: Of the 84 patients without a preoperative tissue diagnosis of malignance, 64 had blind-PD and 20 had ampullectomy (AMP) with intraoperative frozen section.
  • Final pathological diagnosis was benign in ten of 64 blind-PD-treated patients.
  • CONCLUSIONS: Our data support a selective use of blind-PD because (1) a significant portion (65%) of benign ampullary neoplasms can be safely and effectively treated by AMP, (2) blind-PD does not treat ampullary cancer at earlier stage, and (3) blind-PD is associated with significantly more complications and significantly longer hospital stay than AMP.
  • However, blind-PD is strongly recommended for patients with large ampullary neoplasms (>3 cm in diameter), with jaundice, or with malignant endoscopic appearance.
  • [MeSH-major] Ampulla of Vater / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Hospital Mortality / trends. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Probability. Registries. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] World J Surg. 1999 Feb;23(2):158-62; discussion 162-3 [9880425.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):617-22 [19122504.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] J Gastrointest Surg. 2006 Sep-Oct;10(8):1140-3 [16966033.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):32-41 [12704445.001]
  • [Cites] Ann Chir. 2004 Mar;129(2):73-8 [15050176.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Am Surg. 2004 Jan;70(1):6-10; discussion 11-2 [14964538.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1300-6 [16332486.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1855-61 [18415651.001]
  • [Cites] Pancreas. 1995 Oct;11(3):283-8 [8577683.001]
  • [Cites] Endoscopy. 2003 May;35(5):402-6 [12701011.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1188-96 [1746684.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] Endoscopy. 2005 May;37(5):444-8 [15844023.001]
  • (PMID = 19557483.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Yeh CC, Jeng YM, Ho CM, Hu RH, Chang HP, Tien YW: Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg; 2010 Dec;34(12):2945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age.
  • BACKGROUND: Although pancreaticoduodenectomy (PD) provides the best chance of survival for elderly patients with ampullary carcinoma, it is associated with considerable surgical risk.
  • The aim of the present study was to compare the benefits and risks of pancreaticoduodenectomy as a treatment of ampullary carcinoma between young and elderly patients.
  • Comparison of the biological aggressiveness of ampullary cancer between old and younger patients was also performed by immunohistochemical study of several prognostic biological markers, including MUC1, MUC2, CK17, and CDX2.
  • RESULTS: For patients in whom ampullary carcinoma was presumed resectable preoperatively, actuarial survival was significantly poorer in 55 elderly patients because 9 of them did not have PD (the other 46 had PD) than in 101 younger patients (all had PD).
  • There were no significant differences in MUC1, CK17, MUC2, and CDX2 immunohistochemical staining of ampullary carcinomas between elderly and young patients.
  • CONCLUSIONS: Our data support the conclusion that ampullary cancers in elderly patients should be treated as aggressively as in younger patients.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):201-10 [15615658.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] World J Surg. 2006 Nov;30(11):1992-2001; discussion 2002-3 [16957825.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):426-34; discussion 434-7 [7574924.001]
  • [Cites] Br J Cancer. 1997;75(4):593-6 [9052416.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):532-5; discussion 535-6 [1670220.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Br J Surg. 1998 May;85(5):607-10 [9635804.001]
  • [Cites] Arch Surg. 2003 Oct;138(10):1061-7 [14557121.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • (PMID = 20714897.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Bhangle SD, Kramer N, Rosenstein ED: Spondyloarthropathy after ampullary carcinoma resection: "post-Whipple" disease. J Clin Rheumatol; 2009 Aug;15(5):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spondyloarthropathy after ampullary carcinoma resection: "post-Whipple" disease.
  • The development of bowel-bypass syndrome complicating the Whipple procedure for biliary tract carcinoma is described here for the first time.
  • A 56-year-old HLA-B27 + man, treated with excision of adenocarcinoma of the ampulla of Vater, developed an undifferentiated spondyloarthropathy, initially unresponsive to nonsteroidal anti-inflammatory drugs and doxycycline, but eventually controlled with sulfasalazine and tapered corticosteroids.

  • Genetic Alliance. consumer health - Whipple disease.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19590445.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


61. Collins AM, Winter DC, McCormick AP, Cottell DC, Geoghegan JG: Amiodarone hepatotoxicity complicating obstructive jaundice due to ampullary cancer. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):435-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amiodarone hepatotoxicity complicating obstructive jaundice due to ampullary cancer.
  • We present a case of adenocarcinoma of the ampulla of Vater with concurrent amiodarone hepatotoxicity.
  • Endoscopic biopsy identified an ampullary adenoma.
  • [MeSH-major] Adenoma / complications. Amiodarone / toxicity. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / complications. Jaundice, Obstructive / etiology. Liver / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690045.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] N3RQ532IUT / Amiodarone
  •  go-up   go-down


62. Kamisawa T, Horiguchi S, Hayashi Y, Yun X, Yamaguchi T, Tsuruta K, Sasaki T: K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis. J Gastroenterol; 2010 Jul;45(7):771-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis.
  • BACKGROUND: Pancreatic cancer occurs in some patients with autoimmune pancreatitis (AIP).
  • AIP may be a pancreatic lesion of IgG4-related systemic disease.
  • Gastric and colonic cancer can occur during the follow up of AIP patients.
  • We examined K-ras mutations in the major duodenal papilla and gastric and colonic mucosa of AIP patients.
  • METHODS: K-ras analysis and/or immunohistochemical study was performed on the tissues of the major duodenal papilla (n = 8), gastric mucosa (n = 5), colonic mucosa (n = 3), pancreas (n = 5), common bile duct (n = 5), and gallbladder (n = 4) of 12 AIP patients.
  • RESULTS: Significant K-ras mutations were detected in the major duodenal papilla of 4 of 8 cases [GAT (n = 4)], in the gastric mucosa of 2 of 4 cases [AGT (n = 2)], and in the colonic mucosa of 2 of 3 cases [GAT (n = 2)].
  • CONCLUSIONS: Significant K-ras mutations were frequently detected in the major duodenal papilla and gastric and colonic mucosa of AIP patients.
  • AIP patients may have risk factors for gastric and colonic cancer, but the mechanisms of K-ras mutation and its clinical implications are not clear.
  • [MeSH-minor] Adult. Aged. Ampulla of Vater / metabolism. Colon / metabolism. Female. Follow-Up Studies. Gastric Mucosa / metabolism. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Mutation. Risk Factors

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20157749.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


63. Zakharash MP, Zakharash IuM, Usova EV: [Using photodynamic method in diagnosis of duodenal major papilla cancer]. Klin Khir; 2009 Jul-Aug;(7-8):44-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using photodynamic method in diagnosis of duodenal major papilla cancer].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218369.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


64. Barauskas G, Gulbinas A, Pranys D, Dambrauskas Z, Pundzius J: Tumor-related factors and patient's age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg; 2008;15(4):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-related factors and patient's age influence survival after resection for ampullary adenocarcinoma.
  • BACKGROUND/PURPOSE: The majority of surgeons agree that ampullary adenocarcinoma should be removed by partial pancreatoduodenectomy.
  • Favoring extended resection, based on the uncertainty of the preoperative diagnosis and the higher probability of clear resection margins, we aimed to disclose the results of this surgical procedure in terms of postoperative morbidity and mortality, and to identify prognosticators of long-term survival.
  • METHODS: We documented, prospectively, 25 consecutive patients with adenocarcinoma of the papilla of Vater in whom pylorus-preserving pancreatoduodenectomy was performed.
  • Clinical data, pathology reports, International Union Against Cancer (UICC) tumor stage, postoperative morbidity, mortality, and long-term follow-up results were evaluated.
  • CONCLUSIONS: Pancreatoduodenectomy for ampullary carcinoma is reasonable in terms of postoperative morbidity and mortality.
  • [MeSH-major] Adenocarcinoma / mortality. Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670845.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Pujal J, Capellá G, Real FX: The Wnt pathway is active in a small subset of pancreas cancer cell lines. Biochim Biophys Acta; 2006 Jan;1762(1):73-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Wnt pathway is active in a small subset of pancreas cancer cell lines.
  • Here, we analyze the activity of the Wnt pathway in cultured cells derived from ductal and acinar pancreatic adenocarcinomas using a reporter assay dependent on the activity of the beta-catenin/Tcf4 complex.
  • We find that low-level Wnt activity can be detected in several pancreas cancer lines.
  • Our findings indicate that activation of the Wnt pathway may play a role in a small subset of ductal pancreatic cancers.
  • Alternatively, RWP-1 cells may have been derived from a tumor arising in a structure adjacent to the pancreas such as the biliary tract or the Ampulla of Vater.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Wnt Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137866.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


66. Kubota K, Fujisawa T, Abe Y, Inamori M, Kirikoshi H, Saito S, Nakajima A: Clinical significance of the duodenal papilla in patients with separate orifices for the bile and pancreatic ducts. J Gastroenterol; 2007 Jan;42(1):70-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of the duodenal papilla in patients with separate orifices for the bile and pancreatic ducts.
  • BACKGROUND: There have been few reports of separate orifices (SPO) for the bile and pancreatic ducts.
  • [MeSH-major] Ampulla of Vater / anatomy & histology. Bile Ducts / anatomy & histology. Pancreatic Ducts / anatomy & histology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2006 Oct;20(10 ):1594-9 [16858527.001]
  • [Cites] S Afr J Surg. 1987 Mar;25(1):13-5 [3563730.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):412-21 [8421460.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1582-6 [1584258.001]
  • [Cites] Acta Pathol Jpn. 1980 Mar;30(2):187-94 [7386198.001]
  • [Cites] Pancreas. 1997 Jul;15(1):14-5 [9211487.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1883-90 [2820564.001]
  • [Cites] Anat Rec. 1961 Jan;139:59-68 [14025604.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):361-8 [7032685.001]
  • (PMID = 17322996.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Hwang S, Moon KM, Park JI, Kim MH, Lee SG: Retroduodenal resection of ampullary carcinoid tumor in a patient with cavernous transformation of the portal vein. J Gastrointest Surg; 2007 Oct;11(10):1322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroduodenal resection of ampullary carcinoid tumor in a patient with cavernous transformation of the portal vein.
  • This report describes a carcinoid tumor of the ampulla of Vater for which pancreatoduodenectomy was not feasible because of diffuse cavernous transformation of the portal vein (PV) secondary to main PV obliteration of unknown cause.
  • We performed retroduodenal resection of the ampullary carcinoid with total preservation of the pancreas.
  • The duodenal wall defect was primarily repaired, and the pancreatic and bile ducts were separately reconstructed using Roux-en-Y pancreaticojejunostomy and choledochojejunostomy.
  • [MeSH-major] Ampulla of Vater. Carcinoid Tumor / surgery. Common Bile Duct Neoplasms / surgery. Digestive System Surgical Procedures / methods
  • [MeSH-minor] Aged. Cholangiopancreatography, Magnetic Resonance. Choledochostomy. Humans. Imaging, Three-Dimensional. Male. Pancreatic Ducts / surgery. Pancreaticojejunostomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10 ):835-8 [8884299.001]
  • [Cites] World J Surg. 2005 Feb;29(2):203-7 [15650799.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Curr Treat Options Gastroenterol. 2006 Sep;9(5):371-6 [16942661.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):190-3 [9641898.001]
  • [Cites] Dig Surg. 1998;15(5):398-403 [9845621.001]
  • [Cites] Surg Today. 2005;35(1):91-3 [15622473.001]
  • [Cites] HPB Surg. 2000;11(5):325-30; discussion 330-1 [10674748.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):162-8; discussion 168 [12578411.001]
  • [Cites] Korean J Gastroenterol. 2004 May;43(5):309-15 [15156118.001]
  • [Cites] J Gastroenterol Hepatol. 2005 May;20(5):676-81 [15853978.001]
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1088-93; discussion 1093 [16269379.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):7058-60 [17109507.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Eur J Surg. 2002;168(2):74-7 [12113274.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):371-3 [12749224.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1953-8 [10430376.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):727-31 [15143902.001]
  • (PMID = 17674113.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


68. Vincenzi B, Santini D, Perrone G, Russo A, Adamo V, Rizzo S, Castri F, Antinori A, Alloni R, Crucitti PF, Morini S, Rabitti C, Vecchio FM, Magistrelli P, Coppola R, Tonini G: Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. Ann Oncol; 2009 Jan;20(1):78-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.
  • PATIENTS AND METHODS: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included.
  • CONCLUSIONS: Our preliminary data suggest PML as a novel prognostic tool for ampullary cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689862.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


69. Sugimoto M, Takada T, Yasuda H, Nagashima I, Amano H, Yoshida M, Miura F, Uchida T, Isaka T, Toyota N, Wada K, Takagi K, Kato K: Exceptional ultra-late recurrence of papilla Vater carcinoma after pancreaticoduodenectomy: two cases at 17 and 25 years. Hepatogastroenterology; 2005 May-Jun;52(63):940-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exceptional ultra-late recurrence of papilla Vater carcinoma after pancreaticoduodenectomy: two cases at 17 and 25 years.
  • Cancer of the papilla Vater can remain clinically quiescent for decades prior to regional or distant recurrence.
  • This protracted disease-free interval challenges the concept of a "cure" for cancer of the papilla Vater.
  • In the first case reported here, a 74-year-old female underwent pancreaticoduodenectomy in 1985 for cancer of the papilla Vater revealed histologically as a well-differentiated papillotubular adenocarcinoma, stage IA (UICC classification).
  • The second case is that of an 82-year-old female who underwent pancreaticoduodenectomy in 1974 for cancer of the papilla Vater, histologically a well-differentiated adenocarcinoma, stage IA.
  • In the 25.5 years after the operation, the cancer recurred at the choledochoduodenal anastomosis and involved the liver hilus.
  • The ultra-late recurrences (>15 years) in these cases are highly exceptional and, to our knowledge, this is the first report of such recurrences in cancer of the papilla Vater.
  • Because cancer of the papilla Vater can recur in many prognostically favorable cases after prolonged disease-free intervals, the possibility of delayed recurrence should not be ignored.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / surgery. Neoplasm Recurrence, Local / diagnosis. Pancreaticoduodenectomy. Postoperative Complications / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Follow-Up Studies. Humans. Liver / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966237.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


70. Hou L, Xu J, Gao YT, Rashid A, Zheng SL, Sakoda LC, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Meyers DA, Fraumeni JF Jr, Hsing AW: CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Int J Cancer; 2006 Jun 1;118(11):2847-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary tract cancers, encompassing cancers of the gallbladder, extrahepatic bile duct and ampulla of Vater, are rare but highly fatal malignancies.
  • Endogenous estrogens are thought to play a role in the etiology of gallstones and gallbladder cancer, since both conditions predominate in females and are associated with parity and obesity.
  • The study included 446 cancer cases (254 gallbladder, 139 extrahepatic bile duct, 53 ampullary cancers), 929 biliary stone cases (691 gallbladder, 238 bile duct) and 818 population controls.
  • Relative to those with the A2/A2 genotype, A1 carriers (A1/A1 and A1/A2 genotypes) had an increased risk of gallbladder cancer (odds ratio (OR) = 1.5, 95% confidence interval (CI) = 1.1-2.1).
  • In addition, women with the A1 allele and high parity (> or =3) had a 3-fold risk of gallbladder cancer (OR = 3.3, 95% CI = 1.6-6.9), compared to those with the A2/A2 genotype and lower parity, with the highest risk seen for those also having biliary stones (OR = 4.6, 95% CI = 1.8-11.7, P(interaction) = 0.04).
  • No clear relation was seen between the CYP17 polymorphism and cancers of the bile duct or ampulla of Vater.
  • The association of the CYP17 MspA1 polymorphism with an increased risk of gallbladder cancer, as well as biliary stones among overweight and diabetic individuals, suggests an interplay between genetic and hormonal risk factors in gallbladder disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381022.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase
  •  go-up   go-down


71. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM: Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol; 2005 Mar;29(3):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
  • Pancreatobiliary and ampulla of Vater adenocarcinomas frequently metastasize to regional lymph nodes, liver, or lung and are difficult to diagnose because they lack specific immunohistochemical markers.
  • We studied the expression of cytokeratin 7 (CK7), cytokeratin 17 (CK17), cytokeratin 20 (CK20), CDX2, mucin 1 (MUC1), mucin 2 (MUC2), and mucin 5AC (MUC5AC) in 46 cases of pancreatic ductal carcinoma, 18 ampulla of Vater adenocarcinomas, and 24 intrahepatic cholangiocarcinomas.
  • The expression of MUC1 and CK17 was restricted to pancreatic ductal carcinoma (41 of 46, 89%; 38 of 46, 83%, respectively), the ampullary carcinoma of pancreatobiliary origin (6 of 6, 100%; 5 of 6, 83%, respectively), and intrahepatic cholangiocarcinoma (20 of 24, 83%; 17 of 24, 71%, respectively).
  • MUC2 was rarely expressed in pancreatic ductal carcinoma (1 of 46, 2%) and was negative in the ampullary carcinoma of pancreatobiliary origin and in intrahepatic cholangiocarcinoma.
  • A heterogeneous CDX2 staining pattern was seen in 1 of 6 cases of the ampullary carcinoma of pancreatobiliary origin (17%), 5 of 24 intrahepatic cholangiocarcinomas (21%), and 10 of 46 (22%) pancreatic ductal carcinomas.
  • We concluded that CK17 is a useful marker in separating pancreatobiliary adenocarcinomas from extra-pancreatobiliary nonmucinous adenocarcinomas, including adenocarcinomas from the colon, breast, gynecologic organs, stomach, lung, prostate, thyroid, kidney, and adrenal gland, and malignant mesothelioma.
  • MUC1+/CK17+ can be used as positive markers for pancreatic ductal carcinomas, the ampullary carcinoma of pancreatobiliary origin, and cholangiocarcinomas with positive predictive values of 76%, 83%, and 58%, respectively.
  • [MeSH-major] Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Pancreatic Ductal / pathology. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Keratins / metabolism. Male. Mucins / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725805.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


72. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med; 2010 Apr 8;362(14):1273-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
  • BACKGROUND: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer.
  • METHODS: We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks.
  • Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769. )

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [CommentIn] Z Gastroenterol. 2010 Aug;48(8):850-1 [20687022.001]
  • [CommentIn] N Engl J Med. 2010 Apr 8;362(14):1335-7 [20375411.001]
  • [CommentIn] J Hepatol. 2011 Mar;54(3):577-8 [21112109.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20653076.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20647216.001]
  • [CommentIn] Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):395-7 [20678012.001]
  • (PMID = 20375404.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00262769
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Investigator] Nicholson M; Corrie P; Eatock M; Falk S; Elyan S; Valle J; Anthony A; Nicoll J; Kulkarni R; Osbourne R; Garcia Alonso A; Wasan H; Waters J; Harrison M; Adamson D; Rees C; Bridgewater J; Madhusudan S; McAdam K; Bridgewater J; Maraveyas A; Palmer D; Hickish T; Meyer T; Cunningham D; Iveson T; Middleton G; Slater S; Lofts F; Archer C; Iveson T; Iveson T; Bridgewater J; Mukherjee S; Wadsley J; Gollins S
  •  go-up   go-down


73. Bel Hadj N, Elloumi H, Babba T, Kchaou-Oukaa A, Gargouri D, Kochlef A, Romani M, Kilani A, Kharrat J, Ghorbel A: [Carcinoma of the papilla of Vater. Diagnostic and therapeutic problems. An analysis of 32 Tunisian cases]. Tunis Med; 2006 Nov;84(11):701-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the papilla of Vater. Diagnostic and therapeutic problems. An analysis of 32 Tunisian cases].
  • [Transliterated title] Carcinome de l'ampoule de Vater: problémes diagnostiques et therapeutiques. Analyse d'une série de 32 patients.
  • The aim determine the clinical, morphological, endoscopical and progressive profile of patients with ampullary carcinoma.
  • PATIENTS AND METHODS: Thirty-two patients with a carcinoma of the ampulla of Vater, hospitalised in the Gastro-enterology service of Habib Thameur Hospital (Tunis) (1992-2002) have been analysed retrospectively.
  • Twelve patients (37%) had had a cholecystectomy into the 3 years preceding the diagnosis of the ampullary carcinoma.
  • After endoscopical sphincterectomy, an intra-ampullar exophytic tumour had been found in I case and an infiltrated aspect of the ampulla of Vater in 2 cases.
  • The use of lateral duodenoscopy allowed carrying the positive diagnosis in all cases.
  • Five patients had metastasis at the moment of diagnosis.
  • CONCLUSION: The ampullary carcinoma is a rare tumour diagnosed belated.
  • [MeSH-major] Ampulla of Vater. Carcinoma / diagnosis. Carcinoma / therapy. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294894.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


74. McKay A, Mackenzie S, Sutherland FR, Bathe OF, Doig C, Dort J, Vollmer CM Jr, Dixon E: Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy. Br J Surg; 2006 Aug;93(8):929-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreaticoduodenectomy is the primary treatment for periampullary cancer.
  • Associated morbidity is high and often related to pancreatic anastomotic failure.
  • This paper compares rates of pancreatic fistula, morbidity and mortality after pancreaticoduodenectomy in patients having reconstruction by pancreaticogastrostomy with those in patients having reconstruction by pancreaticojejunostomy.
  • The meta-analysis revealed a higher rate of pancreatic fistula associated with pancreaticojejunostomy reconstruction (relative risk (RR) 2.62 (95 per cent confidence interval (c.i.
  • CONCLUSION: Current literature suggests that the safer means of pancreatic reconstruction after pancreaticoduodenectomy is pancreaticogastrostomy, but much of the evidence comes from observational cohort study data.
  • [MeSH-major] Common Bile Duct Neoplasms / surgery. Gastrostomy / methods. Pancreatectomy / methods. Pancreatic Fistula / surgery. Pancreaticoduodenectomy / adverse effects. Pancreaticojejunostomy / methods
  • [MeSH-minor] Ampulla of Vater / surgery. Cohort Studies. Humans. Prospective Studies. Randomized Controlled Trials as Topic. Risk Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2006 Nov;93(11):1435 [17058311.001]
  • (PMID = 16845693.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


75. Imazu H, Uchiyama Y, Matsunaga K, Ikeda K, Kakutani H, Sasaki Y, Sumiyama K, Ang TL, Omar S, Tajiri H: Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. Scand J Gastroenterol; 2010 Jun;45(6):732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnosis were pancreatic cancer in 11, bile duct cancer in 7, gallbladder cancer in 4 and ampullary cancer in 4.
  • CH-EUS staged correctly in all of these six cases, whereas H-EUS misdiagnosed the depth of invasion in one case of gallbladder cancer and one case of ampullary cancer, and invasion of portal vein in two cases of pancreatic cancer and two cases of bile duct cancer.
  • CONCLUSION: The depth of invasion of biliary cancer and vascular invasion of pancreatic and biliary cancer could be demonstrated more clearly with CH-EUS compared to H-EUS.
  • [MeSH-major] Biliary Tract Neoplasms / ultrasonography. Contrast Media / administration & dosage. Endosonography / methods. Ferric Compounds. Iron. Neoplasm Staging / methods. Oxides. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Injections, Intravenous. Pilot Projects. Preoperative Period. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205504.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Oxides; 0 / Sonazoid; E1UOL152H7 / Iron
  •  go-up   go-down


76. Wasan SM, Ross WA, Staerkel GA, Lee JH: Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol; 2005 Sep;100(9):2056-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of expandable metallic biliary stents in resectable pancreatic cancer.
  • AIM: To compare the efficacy of metal versus plastic stents for biliary strictures in patients with surgically resectable pancreatic cancer.
  • Of the 12 patients with pancreaticoduodenectomy, 10 had pancreatic adenocarcinoma, 1 intraductal papillary mucinous tumor, and 1 ampullary cancer.
  • Of the 35 patients, 27 had pancreatic adenocarcinoma, 5 ampullary cancer, 1 neuroendocrine tumor, 1 microcystic adenoma, and 1 autoimmune pancreatitis.
  • CONCLUSIONS: Contrary to the belief that metal stents are contraindicated for patients with surgically resectable pancreatic cancer, our study demonstrated that metal stents provided a longer patency rate, fewer ERCP sessions, and fewer episodes of cholangitis without adding any intra- or postoperative complications.
  • Therefore, metal stents should be considered for patients with resectable pancreatic cancer, especially if surgery is not immediately planned as more patients are now receiving preoperative chemoradiation.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy. Stents

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128952.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals; 0 / Plastics
  •  go-up   go-down


77. Gandini R, Fabiano S, Pipitone V, Spinelli A, Reale CA, Colangelo V, Pampana E, Romagnoli A, Simonetti G: Management of biliary neoplastic obstruction with two different metallic stents implanted in one session. Cardiovasc Intervent Radiol; 2005 Jan-Feb;28(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of the "one-step" technique using two different metallic stents (Wallstent and Ultraflex) and associated rate of complications was studied in 87 patients with jaundice secondary to malignant biliary obstruction, with bilirubin level less than 15 mg/dl and Bismuth type 1 or 2 strictures.
  • The cause of the obstruction was pancreatic carcinoma in 38 patients (44%), lymph node metastasis in 20 patients (23%), gallbladder carcinoma in 13 patients (15%), cholangiocarcinoma in 12 patients (14%) and ampullary carcinoma in four patients (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772722.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Shrikhande SV, Barreto G, Shukla PJ: Pancreatic fistula after pancreaticoduodenectomy: the impact of a standardized technique of pancreaticojejunostomy. Langenbecks Arch Surg; 2008 Jan;393(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic fistula after pancreaticoduodenectomy: the impact of a standardized technique of pancreaticojejunostomy.
  • BACKGROUND: The leading cause for morbidity and mortality after pancreaticoduodenectomy is a pancreatic anastomotic leak and fistula.
  • AIM: The goal is to study the impact of a standardized technique of pancreatic anastomosis (PJ) after pancreaticoduodenectomy in a tertiary referral cancer teaching hospital.
  • RESULTS: There were 144 pancreaticoduodenectomies performed during period A with a pancreatic fistula rate of 16%.
  • During period B, 123 pancreaticoduodenectomies were performed with a pancreatic fistula rate of 3.2% (p < 0.0005).
  • CONCLUSIONS: It appears that a standardized approach to the pancreatic anastomosis and a consistent practice of a single technique can help to reduce the incidence of complications after pancreaticoduodenectomy.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Pancreatic Fistula / etiology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / standards. Pancreaticojejunostomy / standards. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):225-32 [10481115.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):767-71, discussion 771-3 [16327486.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):356-61 [15672425.001]
  • [Cites] Am J Surg. 2005 Jun;189(6):720-9 [15910726.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1642-9 [16311866.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):171-83 [17236843.001]
  • [Cites] ANZ J Surg. 2004 Nov;74(11):945-50 [15550080.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):138-41 [11918876.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):847-54 [12417505.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2117-27 [14645640.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(6):733-7 [12658408.001]
  • [Cites] Br J Surg. 2006 Aug;93(8):929-36 [16845693.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):283-5 [11943127.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1245-51 [12296891.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Am J Surg. 1998 Sep;176(3):274-8 [9776158.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 17703319.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Spyropoulou D, Vassiliou V, Tzelepi V, Kardari M, Tsamandas AC, Kardamakis D: Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature. J Gastrointest Cancer; 2007;38(2-4):95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature.
  • AIM: To report a rare case of metastasis from an adenocarcinoma of the ampulla of Vater to the parotid gland.
  • PATIENTS AND METHODS: In February 2004, a 61-year-old male underwent Whipple surgery due to a grade II adenocarcinoma of the ampulla of Vater (stage IB:pT2N0M0).
  • Fine needle aspiration showed that the infiltrating mass was due to an adenocarcinoma of the ampulla of Vater.
  • CONCLUSIONS: Metastasis of adenocarcinoma of the ampulla of Vater to the parotid gland has not to our knowledge been previously reported.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Parotid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 1963 Nov;87:757-64 [14058839.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2005 Feb;122(1):18-20 [15851941.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):190-2 [3971828.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Otolaryngol Pol. 2005;59(4):547-52 [16273860.001]
  • [Cites] J Surg Oncol. 1976;8(2):183-90 [1263521.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Feb;8(2):139-44 [8723418.001]
  • [Cites] Diagn Cytopathol. 2006 Aug;34(8):580-4 [16850487.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Int J Urol. 2004 Oct;11(10):894-6 [15479296.001]
  • [Cites] Australas Radiol. 2004 Mar;48(1):88-92 [15027931.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Jan;57(1):47-50 [16503033.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):264-5 [17462982.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2007;69(1):51-6 [17085953.001]
  • (PMID = 19016351.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Akoglu S, Uçan ES, Celik G, Sener G, Sevinç C, Kilinç O, Itil O: Endobronchial metastases from extrathoracic malignancies. Clin Exp Metastasis; 2005;22(7):587-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial metastases (EBM) from extrapulmonary malignant tumors are rare.
  • Primary tumors included breast (3), colorectal (3), and renal (2) carcinomas; Malignant Melanoma (2); synovial sarcoma (1), ampulla of Vater adenocarcinoma (1), pheochromocytoma (1), hypernephroma (1), and Hodgkin's Disease (1).
  • The mean interval from initial diagnosis to diagnosis of EBM was 32.8 months (range, 0-96 months) and median survival time was 18 months (range, 4-84).
  • Symptoms and radiographic findings are similar with those in primary lung cancer.
  • Therefore, EBM should be discriminated from primary lung cancer histopathologically.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1975 Apr;135(4):543-7 [1138668.001]
  • [Cites] Chest. 2001 Mar;119(3):768-75 [11243955.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Sep;106(3):537-42 [8361198.001]
  • [Cites] J Surg Oncol. 1996 Aug;62(4):249-52 [8691837.001]
  • [Cites] Acta Oncol. 2004;43(1):73-9 [15068323.001]
  • [Cites] Chest. 1999 Feb;115(2):511-21 [10027454.001]
  • [Cites] Strahlenther Onkol. 2002 Aug;178(8):442-5 [12240550.001]
  • [Cites] Lung Cancer. 2000 May;28(2):163-70 [10717334.001]
  • [Cites] Chest. 1989 Nov;96(5):1110-4 [2805842.001]
  • [Cites] Rev Mal Respir. 2004 Feb;21(1):137-40 [15260048.001]
  • [Cites] Leuk Lymphoma. 1996 Jan;20(3-4):229-37 [8624461.001]
  • [Cites] J Thorac Cardiovasc Surg. 1980 Apr;79(4):499-503 [7359928.001]
  • [Cites] Tumori. 1992 Aug 31;78(4):270-3 [1466085.001]
  • [Cites] Cancer. 1986 May 1;57(9):1750-5 [3955520.001]
  • [Cites] Respir Med. 2003 Jan;97(1):27-9 [12556007.001]
  • [Cites] Respir Med. 2000 Apr;94(4):369-72 [10845436.001]
  • [Cites] Chest. 1985 Jul;88(1):84-8 [4006560.001]
  • [Cites] Eur Radiol. 1996;6(5):596-606 [8934121.001]
  • [Cites] Acta Radiol. 1991 Nov;32(6):455-60 [1742126.001]
  • [Cites] Chest. 1994 Feb;105(2):454-7 [8306746.001]
  • [Cites] Thorax. 1982 May;37(5):362-5 [7112472.001]
  • [Cites] Respiration. 2001;68(4):406-10 [11464090.001]
  • (PMID = 16475029.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


81. Takeda T, Makita K, Okita K, Haba A, Xianhui D: [Intratumoral injection of immature dendritic cells (DC) for cancer patients]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1574-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intratumoral injection of immature dendritic cells (DC) for cancer patients].
  • We proceeded with DC immunotherapy for 21 cancer patients.
  • Immature dendric cells were injected intratumorally to the 16 patients, and three good and effective cases were obtained: case 1: A 69-year-old male patient with papilla-vater carcinoma, case 2: A 49-year-old female patient with gastric cancer, case 3: A 66-year-old male patient with malignant melanoma.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / therapy. Dendritic Cells / immunology. Immunotherapy / methods. Maxillary Neoplasms / therapy. Melanoma / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315873.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Kibria R, Ali SA, Butt S, Akram S: Biliary obstruction and pancreatitis caused by diffuse nodular hyperplasia of Brunner's gland. J Gastrointest Cancer; 2009;40(3-4):128-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We report an unusual case of diffuse BGH of duodenum involving the ampulla of Vater that led to this clinical presentation.
  • CONCLUSION: Albeit its uncommon clinical presentation, it can become challenging in terms of diagnosis and management.
  • A high index of suspicion is of paramount importance for establishing the correct diagnosis and treatment.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1973 Jul;65(1):36-42 [4124404.001]
  • [Cites] Gut. 1985 Feb;26(2):198-202 [3967837.001]
  • [Cites] Gastrointest Endosc. 1998 May;47(5):403-7 [9609436.001]
  • [Cites] Dig Surg. 2007;24(6):452-5 [18025786.001]
  • [Cites] Am J Gastroenterol. 1995 Feb;90(2):290-4 [7847303.001]
  • [Cites] Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):11-4 [18341972.001]
  • [Cites] J Clin Gastroenterol. 1982 Apr;4(2):127-31 [7086105.001]
  • [Cites] Gastrointest Endosc. 1985 Dec;31(6):374-8 [4076734.001]
  • [Cites] South Med J. 1979 Dec;72(12):1537-9 [316193.001]
  • [Cites] Endoscopy. 2000 Dec;32(12):998-1001 [11147953.001]
  • [Cites] Am Surg. 1989 Jul;55(7):474-7 [2662841.001]
  • [Cites] Endoscopy. 1997 Jan;29(1):51 [9083742.001]
  • (PMID = 19924571.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Artifon EL, Couto D Jr, Sakai P, da Silveira EB: Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc; 2009 Aug;70(2):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of EUS versus CT scan for staging of ampullary cancer.
  • BACKGROUND: Malignancies of the biliary and pancreatic systems are associated with a poor prognosis.
  • However, ampullary cancer carries a better prognosis and is often diagnosed when curative treatment is still possible.
  • (1) To determine the test performance characteristics of EUS and CT in loco-regional staging of ampullary neoplasms, and (2) to determine the impact of CT scan results on the test performance characteristics of EUS.
  • Further studies to determine the role of specialized CT protocols in patients with ampullary malignancies are needed.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Endosonography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523619.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Nguyen N, Shah JN, Binmoeller KF: Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma. Endoscopy; 2010 Nov;42(11):975-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma.
  • Outcomes for 14 elderly (age ≥ 70 years) patients (79.4 ± 1.0 years) who underwent endoscopic papillectomy for ampullary tumors were compared with those of 22 younger (age < 70 years) patients (52.5 ± 1.9 years).
  • Whilst all younger patients survived, five elderly patients died but three of these deaths were not cancer-related.
  • Advanced age, therefore, did not adversely influence the outcomes of endoscopic papillectomy, suggesting it may be a treatment of choice for elderly patients with ampullary tumors or early cancer who are deemed unfit for surgery.
  • [MeSH-major] Adenoma, Acidophil / surgery. Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Gastrointestinal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21072717.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Schirmacher P, Büchler MW: Ampullary adenocarcinoma - differentiation matters. BMC Cancer; 2008;8:251
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary adenocarcinoma - differentiation matters.
  • This fuels the discussion about maintaining ampullary cancer as a separate entity.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Differentiation. Diagnosis, Differential. Epithelium / pathology. Humans. Medical Oncology / methods. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):187-91 [18343082.001]
  • [Cites] Surgery. 2006 Nov;140(5):764-72 [17084719.001]
  • [Cites] BMC Cancer. 2008;8:170 [18547417.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • (PMID = 18761739.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2553420
  •  go-up   go-down


86. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol; 2009 Dec;65(1):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
  • PURPOSE: The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, who were not suitable candidates for surgery, were eligible for the study.
  • In the 85 patients who received this UFD chemotherapy in previous and late phase II studies, multivariate analysis revealed the ECOG performance status 1 (P = 0.001), gallbladder as the primary cancer site (P = 0.014), T-factor 4 of the TNM classification (P = 0.035), and elevated serum lactate dehydrogenase levels (P = 0.043) as being associated with a significantly shorter survival.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin had minimum activity against advanced biliary tract cancer.
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / mortality. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404641.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


87. Alibegov RA, Prokhorenko TI, Sergeev OA, Khlusov AN: [Clinico-morphological factors of prognosis in cancer of the major duodenum papilla]. Vestn Khir Im I I Grek; 2008;167(2):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological factors of prognosis in cancer of the major duodenum papilla].
  • Long-term results of radical operative treatment of 19 patients with cancer of the major duodenal papilla were analyzed.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Disease Progression. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging / methods. Pancreatic Neoplasms / pathology. Prognosis. Retrospective Studies. Russia / epidemiology. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522181.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


88. Saito H, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Tsuyuguchi T, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F, Japanese Association of Biliary Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japan Society of Clinical Oncology: Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg; 2008;15(1):63-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas.
  • The purpose of radiation therapy for unresectable biliary tract cancer is to prolong survival or prolong stent patency, and to provide palliation of pain.
  • For unresectable bile duct cancer, there are a number of studies showing that radiation therapy is superior to the best supportive care.
  • Unresectable gallbladder cancer with a large focus is usually extensive, and normal organs with high radio sensitivity exist contiguously with it.
  • Therefore, only limited anticancer effects are to be expected from external beam radiation therapy for this type of cancer.
  • The number of reports on ampullary cancer is small and the role of radiation therapy in this cancer has not been established.
  • Combination treatment for ampullary cancer consists of either a single use of intraoperative radiation therapy, postoperative external beam radiation therapy or intraluminal brachytherapy, or a combination of two or three of these therapies.
  • There is an RCT demonstrating that, in unresectable bile duct cancer, extended survival and improved quality of life (QOL) have been achieved through a combination of photodynamic therapy and biliary stenting, compared with biliary stenting alone.
  • [MeSH-major] Ampulla of Vater. Biliary Tract Neoplasms / therapy. Carcinoma. Photochemotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2003 Nov;125(5):1355-63 [14598251.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):105-12 [12909222.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):954-7 [15239222.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):673-7 [15226765.001]
  • [Cites] Surgery. 1985 Oct;98(4):752-9 [4049246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35 [9369143.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1585-91 [10430299.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:215-20 [10436826.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):21-3 [15685030.001]
  • [Cites] Endoscopy. 2005 May;37(5):425-33 [15844020.001]
  • [Cites] Radiat Med. 2005 May;23(3):200-7 [15940068.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2426-30 [16279895.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):2-6 [18274838.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):536-44 [3942986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):331-8 [3104245.001]
  • [Cites] J Natl Cancer Inst. 1988 Jul 20;80(10):751-5 [2898536.001]
  • [Cites] Semin Liver Dis. 1990 May;10(2):131-41 [2162565.001]
  • [Cites] Am J Surg. 1991 Apr;161(4):454-8 [1709795.001]
  • [Cites] World J Surg. 1991 May-Jun;15(3):357-66 [1853615.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):433-7 [1951179.001]
  • [Cites] Eur J Surg. 1991 Oct;157(10):587-9 [1687249.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8 [7794082.001]
  • [Cites] Hepatology. 2000 Feb;31(2):291-8 [10655248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):913-9 [10705013.001]
  • [Cites] Cancer J. 2002 Jan-Feb;8(1):74-8 [11895206.001]
  • [Cites] World J Surg. 2003 Feb;27(2):173-9 [12616432.001]
  • [Cites] Gastrointest Endosc. 2003 Jun;57(7):860-7 [12776033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65 [14630274.001]
  • (PMID = 18274845.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2794340
  • [Investigator] Kai M; Kimura Y; Sawada S; Shimizu H; Nakagawara H; Nakachi K; Yoshitome H; Saisyo H; Ryu M; Shikata S; Nimura Y
  •  go-up   go-down


89. Chang MC, Chang YT, Sun CT, Chiu YF, Lin JT, Tien YW: Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of Vater. World J Surg; 2007 May;31(5):1135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of Vater.
  • Recent studies have revealed that genes and proteins related to cell cycle and apoptosis regulation may be involved in pancreatic carcinogenesis.
  • All periampullary cancer tissue samples were examined by a pathologist, who was unaware of the parameters to be investigated.
  • A total of 68 patients with periampullary cancers (29 ampulla of Vater cancers (AVCs) and 39 pancreatic ductal cancers (PDCs), including various stages and histological subtypes, were enrolled.
  • [MeSH-major] Ampulla of Vater / metabolism. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / metabolism. Common Bile Duct Neoplasms / surgery. Cyclin D1 / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / surgery


90. Konstadoulakis MM, Filippakis GM, Lagoudianakis E, Antonakis PT, Dervenis C, Bramis J: Intra-arterial bolus octreotide administration during Whipple procedure in patients with fragile pancreas: a novel technique for safer pancreaticojejunostomy. J Surg Oncol; 2005 Mar 15;89(4):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic fistula rate is higher in cases of fragile pancreas often seen in duodenal carcinomas and carcinomas of the ampulla of Vater.
  • Due to its physiologic effects to the pancreatic parenchyma the intra-arterial administration of octreotide could provide tissue hardening that allows for a technically easier anastomosis while maintaining its protective role for fistula formation.
  • METHODS: Octreotide was injected directly into the distal part of the gastroduodenal artery (GDA) in four patients undergoing Whipple for histologically proven periampullary cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Cutaneous Fistula / prevention & control. Octreotide / administration & dosage. Pancreatic Fistula / prevention & control. Pancreaticojejunostomy / methods. Postoperative Complications / prevention & control
  • [MeSH-minor] Aged. Ampulla of Vater. Anastomosis, Surgical / methods. Common Bile Duct Neoplasms / surgery. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Pancreas / pathology. Pancreaticoduodenectomy. Parenteral Nutrition, Total

  • MedlinePlus Health Information. consumer health - After Surgery.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726611.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


91. Grau AM, Ballard BR: Transduodenal excision of bleeding periampullary endocrine tumor as a bridge to pancreaticoduodenectomy in a Jehovah's Witness patient. J Gastrointest Surg; 2006 Mar;10(3):428-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transduodenal excision of the ampullary mass was successfully performed as a bridge to pancreaticoduodenectomy in this critically ill patient.
  • Finally, we reviewed the role of transduodenal excision in the management of ampullary tumors and describe its use as a bridge to pancreaticoduodenectomy in a patient with a malignant neoplasm of the ampulla.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Jehovah's Witnesses. Pancreaticoduodenectomy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):943-8 [14644282.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Eur J Surg Oncol. 1999 Feb;25(1):90-3 [10188863.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2003 Aug;17(4):528-35 [12968246.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):272-4 [12630039.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):190-3 [9641898.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Int J Pancreatol. 2001;29(1):59-62 [11558634.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Can J Anaesth. 2002 Apr;49(4):402-8 [11927481.001]
  • [Cites] Endoscopy. 1998 Aug;30(6):538-43 [9746162.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):869-74 [12417508.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):27-33 [10385718.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):32-41 [12704445.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):355-8 [9324155.001]
  • [Cites] Eur J Surg. 1996 Dec;162(12):961-7 [9001878.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1397-403 [7526810.001]
  • [Cites] Pancreas. 2002 Apr;24(3):258-63 [11893933.001]
  • [Cites] Transfusion. 2002 Jul;42(7):812-8 [12375651.001]
  • [Cites] Am Surg. 1992 Feb;58(2):92-5 [1550312.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1055-60 [8874456.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1227-31 [10586341.001]
  • [Cites] Am J Surg. 1994 Jul;168(1):66-8 [7912910.001]
  • [Cites] Surg Today. 1993;23(11):1018-22 [7904839.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):349-57 [10049419.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):19-34 [15027883.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Eur J Surg. 1998 Oct;164(10):765-70 [9840306.001]
  • [Cites] Arch Surg. 1992 Mar;127(3):349-51 [1347993.001]
  • [Cites] World J Surg Oncol. 2004 Aug 15;2:28 [15310407.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):239-44 [15368107.001]
  • [Cites] Am J Surg. 1990 Mar;159(3):320-4 [2305940.001]
  • [Cites] Transfusion. 1994 May;34(5):396-401 [8191563.001]
  • (PMID = 16504891.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA 091408-02
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


92. Guercioni G, Marmorale C, Siquini W, Fianchini M, Fianchini A, Landi E: Incidental small ampullary somatostatinoma treated with ampullectomy 2 years after diagnosis. Dig Dis Sci; 2006 Oct;51(10):1767-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental small ampullary somatostatinoma treated with ampullectomy 2 years after diagnosis.
  • Somatostatinomas are rare tumors; ampullary somatostatinomas are very rare.
  • We report a case of a small pure somatostatin-producing neuroendocrine tumor of ampulla of Vater in a 54-year-old woman with neither neurofibromatosis nor somatostatinoma syndrome, "incidentally" discovered during an abdominal computed tomography.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Somatostatinoma / surgery

  • Genetic Alliance. consumer health - Somatostatinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1977 Mar 26;1(8013):666-8 [66472.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10):2162-5 [11680591.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1405-8 [10235228.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1825-35 [7562050.001]
  • [Cites] Cancer. 1977 Jun;39(6):2451-9 [872045.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):527-42 [11459269.001]
  • [Cites] Arch Surg. 1985 Dec;120(12):1381-3 [2865941.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1979 Dec;44(6):2273-9 [509396.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):519-23 [1310159.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):869-74 [12417508.001]
  • [Cites] Am J Gastroenterol. 1989 Nov;84(11):1452-5 [2573269.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):415-7 [11606861.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):146-52 [10792774.001]
  • [Cites] Pathol Res Pract. 1988 Feb;183(1):8-16 [2834706.001]
  • [Cites] Surg Gynecol Obstet. 1993 Sep;177(3):269-78 [8102815.001]
  • [Cites] N Engl J Med. 1977 Apr 28;296(17):963-7 [321960.001]
  • [Cites] Surgery. 1993 Dec;114(6):1144-7 [8256221.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):263-81 [2820062.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):498-502 [6318950.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):13-22 [10374671.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):503-4 [10430168.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):67-73 [7745981.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):33-7 [2867674.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):159 [6318875.001]
  • [Cites] J Surg Oncol. 1987 Sep;36(1):8-16 [3041116.001]
  • (PMID = 16967313.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P: [Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases]. Zhonghua Yi Xue Za Zhi; 2005 Mar 2;85(8):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was accomplished on the clinical manifestation, pathological behavior and postoperative survival of 631 patients with periampullary cancer hospitalized from Jan 1980 to Dec 2003.
  • RESULTS: The characteristics of different periampullary cancers, in the order of carcinoma of head of pancreas (n = 352), carcinoma of common bile duct (n = 42), carcinoma of Vater's ampulla (n = 189), and duodenal cancer (n = 48) were as follows:.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949327.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Alsaif F: Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option? Saudi J Gastroenterol; 2010 Apr-Jun;16(2):75-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option?
  • Pancreaticoduodenectomy (PD) is the standard surgical treatment for resectable peri-ampullary tumors.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Pylorus
  • [MeSH-minor] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Blood Loss, Surgical. Blood Transfusion. Female. Follow-Up Studies. Gastric Emptying / physiology. Hospital Mortality / trends. Humans. Intraoperative Complications / mortality. Length of Stay. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Postoperative Complications / mortality. Postoperative Complications / prevention & control. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Jan;24(1):66-70; discussion 70-1 [10594206.001]
  • [Cites] Surg Gynecol Obstet. 1946 Jun;82:623-31 [20983134.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):193-7 [10982613.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1236-41; discussion 1242 [11071469.001]
  • [Cites] Dig Dis Sci. 2000 Oct;45(10):1907-12 [11117559.001]
  • [Cites] J Gastroenterol. 2002;37(8):596-603 [12203074.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):859-65 [12788421.001]
  • [Cites] Surgery. 2003 Jun;133(6):647-55 [12796733.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):758-65 [13129553.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):743-6 [15191869.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Ann Surg. 1980 Sep;192(3):306-10 [7416828.001]
  • [Cites] Surgery. 1989 May;105(5):645-53 [2650006.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 1997 Oct;185(4):373-9 [9328386.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):467-70 [9874435.001]
  • [Cites] World J Surg. 1999 Sep;23(9):920-5 [10449821.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):354-9 [10473855.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):303-11 [10526067.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):222-7 [15827814.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):328-31 [15905037.001]
  • [Cites] World J Surg. 2005 Jul;29(7):873-9; discussion 880 [15951944.001]
  • [Cites] World J Surg. 2005 Jul;29(7):881-4 [15951940.001]
  • [Cites] World J Surg. 2005 Oct;29(10):1319-24 [16284796.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1825-34 [17342566.001]
  • [Cites] World J Surg. 2007 Aug;31(8):1606-15 [17566824.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(3):262-9 [18535763.001]
  • [Cites] J Med Assoc Thai. 2008 May;91(5):693-8 [18672634.001]
  • [Cites] Eur J Surg Oncol. 2008 Nov;34(11):1237-45 [18242943.001]
  • [CommentIn] Saudi J Gastroenterol. 2010 Apr-Jun;16(2):65 [20339172.001]
  • (PMID = 20339174.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC3016509
  •  go-up   go-down


95. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS: Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem; 2006 Jun;52(6):1062-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
  • BACKGROUND: Cell-free DNA circulating in blood is a candidate biomarker for malignant tumors.
  • Unlike uniformly truncated DNA released from apoptotic nondiseased cells, DNA released from dead cancer cells varies in size.
  • We developed a novel method to measure the ratio of longer to shorter DNA fragments (DNA integrity) in serum as a potential biomarker for patients with colorectal cancer (CRC) or periampullary cancers (PACs).
  • [MeSH-major] Ampulla of Vater. Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / diagnosis. Colorectal Neoplasms / diagnosis. Common Bile Duct Neoplasms / diagnosis. DNA / blood. Duodenal Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis


96. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y: Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case. Surg Today; 2008;38(5):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case.
  • A 58-year-old man who had undergone total colectomy for FAP 18 years earlier was hospitalized for carcinoma arising from the residual rectum.
  • He had severe diabetes mellitus, but had no symptoms of pancreatic exocrine dysfunction.
  • Upper endoscopy showed multiple duodenal adenomas including carcinoma involving the papilla of Vater.
  • To remove these duodenal adenomas and ampullary carcinoma and prevent recurrent pancreatitis, we performed pancreaticoduodenectomy.
  • On pathologic examination, the major duodenal papilla was completely obstructed by the carcinoma, and the minor papilla was also involved by the adenoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Adenomatous Polyposis Coli / complications. Ampulla of Vater. Common Bile Duct Neoplasms / etiology. Pancreatic Neoplasms / etiology. Pancreatitis / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Pancreatic Ducts. Pancreaticoduodenectomy. Recurrence


97. Singh S, Sachdev AK, Chaudhary A, Agarwal AK: Palliative surgical bypass for unresectable periampullary carcinoma. Hepatobiliary Pancreat Dis Int; 2008 Jun;7(3):308-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgical bypass for unresectable periampullary carcinoma.
  • BACKGROUND: Around 60% to 80% of patients with periampullary carcinoma are unresectable either due to distant metastasis or local vascular invasion.
  • This study was conducted to assess the results of palliative surgical bypass for patients with unresectable periampullary carcinoma at our hospital, a tertiary referral center of Northern India.
  • METHOD: The study group comprised 204 patients who had undergone surgical bypass for advanced periampullary carcinoma over the last 15 years.
  • RESULTS: Between January 1990 and December 2004, 204 patients (128 males, 76 females) consisting of 179 patients with carcinoma of head of the pancreas, 14 patients with ampullary carcinoma, 8 patients with lower end cholangiocarcinoma and 3 patients with duodenal carcinoma underwent surgical bypass.
  • [MeSH-major] Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Gastrostomy / methods. Jejunostomy / methods. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522888.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Bezrodnyĭ BH, Korotkyĭ VM, Khomenko DI: [Performance of reconstruction stage of the pancreatic-duodenal resection for the cancer of the pancreatic head and periampullary zone]. Klin Khir; 2009 Jul-Aug;(7-8):11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Performance of reconstruction stage of the pancreatic-duodenal resection for the cancer of the pancreatic head and periampullary zone].

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218357.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


99. Honda G, Kurata M, Matsumura H, Matsumoto H, Kamisawa T, Egawa N: Laparoscopy-assisted transduodenal papillectomy. Dig Surg; 2010;27(2):123-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Basically, patients with cancer of the major duodenal papilla should undergo pylorus-preserving pancreatoduodenectomy; however, patients with adenoma or cancer in adenoma do not require prophylactic lymph node dissection, so they are indicated for limited resection of the major duodenal papilla.
  • Endoscopic snare resection (ESR) has developed as limited resection of the major duodenal papilla; however, the ESR technique is still restricted to certain centers, because its outcome depends on the technical skills of the endoscopist.
  • The duodenum was opened opposite to the major duodenal papilla, and the major duodenal papilla was resected extracorporeally.
  • After resection, the resection stumps of the bile duct and the pancreatic duct were sutured along with the duodenal mucosa.
  • RESULTS: We performed LATDP in 2 patients with cancer in adenoma.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Laparoscopy / methods. Pancreaticoduodenectomy / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • (PMID = 20551656.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Peng SY, Hong DF, Liu YB, Li JT, Tao F, Tan ZJ: [A pancreas suture-less type II binding pancreaticogastrostomy]. Zhonghua Wai Ke Za Zhi; 2009 Dec 1;47(23):1764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From November 2008 to May 2009, 26 patients underwent pancreaticoduodenectomy and mid-segmentectomy of pancreas with type II BPG reconstruction, including 13 cases of pancreatic head cancer, 3 cases of duodenal adenocarcinoma, 2 cases of ampullary carcinoma, 4 cases of cholangiocarcinoma, 1 case of bile duct cell severe atypical hyperplasia, and 1 case of stomach cancer.
  • No mortality or pancreatic leakage occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193541.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement